var title_f10_32_10752="Pressures tricuspid regurg pulm HTN";
var content_f10_32_10752=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tricuspid regurgitation due to pulmonary hypertension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pressures, simultaneously recorded in the right atrium (RA) and right ventricle (RV), are markedly elevated in tricuspid regurgitation due to pulmonary hypertension and and there is a tall \"V\" wave in the RA.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Kern MJ (Ed). Hemodynamic Rounds: Interpretation of Cardiac Pathophysiology from Pressure Waveform Analysis. Wiley-Liss, New York, 1993.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10752=[""].join("\n");
var outline_f10_32_10752=null;
var title_f10_32_10753="Urethral caruncle";
var content_f10_32_10753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urethral caruncle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Toby Chai, MD, University of Maryland School of Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10753=[""].join("\n");
var outline_f10_32_10753=null;
var title_f10_32_10754="MRI pancreatic neuroendocrine tumor";
var content_f10_32_10754=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of a neuroendocrine tumor of the pancreas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Malignant neuroendocrine tumor of the pancreas. T1-weighted gradient echo image of abdomen demonstrates mass (arrow) near junction of pancreatic body and tail. Note that mass (arrow) is lower in signal intensity than adjacent normal pancreatic parenchyma (arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Leyendecker JR, Brown JJ. Practical Guide to Abdominal and Pelvic MRI. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10754=[""].join("\n");
var outline_f10_32_10754=null;
var title_f10_32_10755="Tropicamide: Pediatric drug information";
var content_f10_32_10755=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tropicamide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/58/8100?source=see_link\">",
"    see \"Tropicamide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/27/12724?source=see_link\">",
"    see \"Tropicamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mydriacyl&reg;;",
"     </li>",
"     <li>",
"      Tropicacyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F232089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diotrope&reg;;",
"     </li>",
"     <li>",
"      Mydriacyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ophthalmic Agent, Mydriatic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Mydriasis: Instill 1 drop (0.5%) 15-20 minutes prior to procedure (1% concentration may be required in patients with heavily pigmented irides);",
"     <b>",
"      Note:",
"     </b>",
"     In premature neonates, use of 1% solution, while effective, has been associated with significant increases in mean blood pressure when used simultaneously with phenylephrine eye drops (Chew, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/58/8100?source=see_link\">",
"      see \"Tropicamide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cycloplegia: Instill 1-2 drops (1%); may repeat in 5 minutes. The exam must be performed within 30 minutes after the repeat dose; if the patient is not examined within 20-30 minutes, instill an additional drop. Concentrations &lt;1% are inadequate for producing satisfactory cycloplegia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mydriasis: Instill 1-2 drops (0.5%) 15-20 minutes before exam; may repeat every 30 minutes as needed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F232076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 0.5% (15 mL); 1% (2 mL, 3 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mydriacyl&reg;: 1% (3 mL, 15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tropicacyl&reg;: 0.5% (15 mL); 1% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F232061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: To minimize systemic absorption, apply finger pressure on the lacrimal sac for 1-2 minutes following instillation of the ophthalmic solution; avoid contact of bottle tip with skin or eye",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; do not refrigerate",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-acting mydriatic used in diagnostic procedures; as well as preoperatively and postoperatively; treatment of some cases of acute iritis, iridocyclitis, and keratitis",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F232125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, tachycardia, vascular congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, parasympathetic stimulations, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Eczematoid dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dryness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Transient stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, follicular conjunctivitis, increased intraocular pressure, photophobia with or without corneal staining",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tropicamide or any component; glaucoma, adhesions between the iris and the lens",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in infants and children since tropicamide may cause potentially dangerous CNS disturbances and psychotic reactions",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tropicamide may cause an increase in intraocular pressure",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F232071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13971141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevents the sphincter muscle of the iris and the muscle of the ciliary body from responding to cholinergic stimulation producing pupillary dilation and paralysis of accommodation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1050517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum mydriatic effect: &sim;20-40 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: &sim;6-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum cycloplegic effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak: 20-35 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: &lt;6 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/27/12724?source=see_link\">",
"      see \"Tropicamide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause blurred vision; do not drive or engage in hazardous activities while the pupils are dilated; may cause sensitivity to light; may cause dry mouth",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Caputo AR and Schnitzer RE, &ldquo;Systemic Response to Mydriatic Eyedrops in Neonates: Mydriatics in Neonates,&rdquo;",
"      <i>",
"       J Pediatr Ophthalmol Strabismus",
"      </i>",
"      , 1978, 15(2):109-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/32/10755/abstract-text/368306/pubmed\" id=\"368306\" target=\"_blank\">",
"        368306",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chew C, Rahman RA, Shafie SM, et al, \"Comparison of Mydriatic Regimens Used in Screening for Retinopathy of Prematurity in Preterm Infants With Dark Irides,\"",
"      <i>",
"       J Pediatr Ophthalmol Strabismus",
"      </i>",
"      , 2005, 42(3):166-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/32/10755/abstract-text/15977870/pubmed\" id=\"15977870\" target=\"_blank\">",
"        15977870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12869 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-24EF02F2C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10755=[""].join("\n");
var outline_f10_32_10755=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232088\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232089\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050512\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445211\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050507\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232076\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232061\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050515\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050509\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050514\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232125\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050518\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050506\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050505\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300184\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223549\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232071\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13971141\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050504\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050517\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050511\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12869\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12869|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/58/8100?source=related_link\">",
"      Tropicamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/27/12724?source=related_link\">",
"      Tropicamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_32_10756="Methacholine: Drug information";
var content_f10_32_10756=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methacholine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/22/34147?source=see_link\">",
"    see \"Methacholine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Provocholine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Methacholine Omega;",
"     </li>",
"     <li>",
"      Provocholine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F193947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F193942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     For inhalation only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Challenge test:",
"     </b>",
"     Before inhalation challenge, perform baseline pulmonary function tests; the patient must have an FEV",
"     <sub>",
"      1",
"     </sub>",
"     of at least 70% of the predicted value. The following is a suggested schedule for administration of methacholine challenge. Calculate cumulative units by multiplying number of breaths by concentration given. Total cumulative units is the sum of cumulative units for each concentration given. See following breakdown:",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Methacholine",
"     </caption>",
"     <col align=\"center\" width=\"40\">",
"     </col>",
"     <col align=\"center\" width=\"110\">",
"     </col>",
"     <col align=\"center\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"120\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"bottom\">",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Vial",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Serial Concentration (mg/mL)",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         No. of Breaths",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Cumulative Units per Concentration",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Total Cumulative Units",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         E",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.025",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.125",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.125",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         D",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.25",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1.25",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1.375",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         C",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         12.5",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         13.88",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         B",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         50",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         63.88",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         A",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         125",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         188.88",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Determine FEV",
"     <sub>",
"      1",
"     </sub>",
"     within 5 minutes of challenge, a positive challenge is a 20% reduction in FEV",
"     <sub>",
"      1",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6699693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Children &ge;5 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F193943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F193930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for reconstitution, for oral inhalation, as chloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Provocholine&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F193920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6699694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by inhalation only; oral and injection administration has been associated with nausea, vomiting, substernal pain/pressure, hypotension, fainting, transient complete heartblock, and cardiac arrest.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F193931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnosis of bronchial airway hyperactivity",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F193945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, lightheadedness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Throat irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F193934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methacholine, other parasympathomimetic agents, or any component of the formulation; concomitant use of beta-blockers; repeat administration (other than day of challenge test with increasing doses)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F193924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchoconstriction:",
"     <b>",
"      [U.S. Boxed Warning]: Administer only by inhalation; severe bronchoconstriction and reduction in respiratory function can result.",
"     </b>",
"     Patients with severe hyper-reactivity of the airways can experience bronchoconstriction at a dosage as low as 0.025 mg/mL (0.125 cumulative units). If severe bronchoconstriction occurs, reverse immediately by administration of a rapid-acting inhaled bronchodilator (eg, albuterol).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risk to benefit: Use only in patients with cardiovascular disease, peptic ulcer disease, seizures, thyroid disease, urinary tract obstruction, and vagotonia if benefit outweighs risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Females of childbearing potential: Administration should be within 10 days of the onset of menses or within 2 weeks of a negative pregnancy test.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;5 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: Methacholine is a bronchoconstrictor for diagnostic purposes only.",
"     </b>",
"     Perform inhalation challenge under the supervision of a physician trained in and thoroughly familiar with all aspects of the technique, all contraindications, warnings, and precautions of methacholine challenge and the management of respiratory distress. Have emergency equipment and medication immediately available to treat acute respiratory distress. Product should not be handled by persons with asthma or hay fever.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the adverse/toxic effect of Cholinergic Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F193928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6699689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Avoid use in pregnant women unless the potential benefit justifies the potential risk to the fetus. Administration should be within 10 days of the onset of menses or within 2 weeks of a negative pregnancy test.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6699691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Provocholine Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $44.00",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F193935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Provocholine (IL);",
"     </li>",
"     <li>",
"      Provokit (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F193923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methacholine chloride is a cholinergic (parasympathomimetic) synthetic analogue of acetylcholine. The drug stimulates muscarinic, postganglionic parasympathetic receptors, which results in smooth muscle contraction of the airways and increased tracheobronchial secretions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F193933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 1-4 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 15-75 minutes or 5 minutes if methacholine challenge is followed with a beta-agonist agent",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9622 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10756=[""].join("\n");
var outline_f10_32_10756=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709036\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193940\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193941\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193947\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193942\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6699693\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193943\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193930\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193920\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6699694\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193931\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193945\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193934\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193924\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299681\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221587\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193928\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6699689\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6699691\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323379\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193935\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193923\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193933\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9622\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9622|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/22/34147?source=related_link\">",
"      Methacholine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_32_10757="Lyme disease map US";
var content_f10_32_10757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Reported cases of Lyme disease - United States, 2010",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 406px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    One dot is placed randomly within the county of residence for each confirmed case. Though Lyme disease cases have been reported in nearly every state, cases are reported based on the county of residence, not necessarily the county of infection.",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Reported Cases of Lyme Disease - United States, 2010. United States Centers for Disease Control and Prevention. Available at:",
"     <a href=\"file://www.cdc.gov/lyme/resources/ReportedCasesofLymeDisease.pdf\" target=\"_blank\">",
"      file://www.cdc.gov/lyme/resources/ReportedCasesofLymeDisease.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10757=[""].join("\n");
var outline_f10_32_10757=null;
var title_f10_32_10758="Two stage resection divertic dz";
var content_f10_32_10758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Two stage approaches to resection of diverticular disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 687px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two stage procedures are used in emergency situations where there has been peritoneal contamination. Common among the approaches is that the offending segment of diverticular disease is resected at the first operation. Panel A: stage one consists of the Hartmann operation; the diseased sigmoid colon is removed, the fecal stream is diverted, and the rectum is oversewn; in stage two, intestinal continuity is reestablished by a descending colorectostomy. Panel B: in stage one the diseased sigmoid is removed, and both ends of bowel are brought to the surface, one as an end colostomy and the other as a mucus fistula; in stage two, intestinal continuity is reestablished as in panel A. Panel C: in stage one the diseased sigmoid colon is resected, a colorectostomy is constructed and protected by a diverting transverse colostomy; in stage two there is closure of the transverse colostomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10758=[""].join("\n");
var outline_f10_32_10758=null;
var title_f10_32_10759="Overview of renal tubular acidosis";
var content_f10_32_10759=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of renal tubular acidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/32/10759/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10759/contributors\">",
"     Ellie Kelepouris, MD, FAHA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10759/contributors\">",
"     Zalman S Agus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/32/10759/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10759/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10759/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/32/10759/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10759/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/32/10759/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lungs and the kidneys are responsible for the maintenance of acid-base balance within the body. Alveolar ventilation removes carbon dioxide, while the kidneys reclaim filtered bicarbonate and excrete hydrogen ions produced by the metabolism of dietary protein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10089?source=see_link\">",
"     \"Chapter 11B: Regulation of renal hydrogen excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"renal tubular acidosis\" (RTA) refers to a group of disorders in which, despite a relatively well-preserved glomerular filtration rate, metabolic acidosis develops because of defects in the ability of the renal tubules to perform the normal functions required to maintain acid-base balance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10759/abstract/1\">",
"     1",
"    </a>",
"    ]. All forms of RTA are characterized by a normal anion gap (hyperchloremic) metabolic acidosis. This form of metabolic acidosis usually results from either the net retention of hydrogen chloride or its equivalent (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25411?source=see_link\">",
"     ammonium chloride",
"    </a>",
"    ) or the net loss of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    or its equivalent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10759/abstract/2\">",
"     2",
"    </a>",
"    ]. The major cause of a normal anion gap acidosis in patients without a significant impairment in renal function is diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"     \"Approach to the adult with metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are three major subgroups of RTA with different clinical characteristics (",
"    <a class=\"graphic graphic_table graphicRef58428 \" href=\"UTD.htm?22/42/23211\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Distal or type 1 RTA",
"     </li>",
"     <li>",
"      Proximal or type 2 RTA",
"     </li>",
"     <li>",
"      Hypoaldosteronism or type 4 RTA",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although initially used to describe a transiently severe form of distal RTA in infants, the term type 3 or mixed RTA is now most often applied to a rare autosomal recessive syndrome (resulting from carbonic anhydrase II deficiency) with features of both distal and proximal RTA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10759/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. In addition to RTA, affected patients suffer from osteopetrosis, cerebral calcification, and mental retardation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17768?source=see_link&amp;anchor=H15#H15\">",
"     \"Etiology and clinical manifestations of renal tubular acidosis in infants and children\", section on 'Mixed (type 3) RTA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A general introduction to the different forms of RTA will be presented here. The acidosis observed in patients with chronic kidney disease is also briefly reviewed, although this disorder is not considered a form of RTA since, by definition, RTA describes conditions in which dysfunction of renal tubule acidification mechanisms occurs with a relatively well-preserved glomerular filtration rate. Detailed discussions of issues related to RTA, including RTA in infants and children, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5860?source=see_link\">",
"     \"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17768?source=see_link\">",
"     \"Etiology and clinical manifestations of renal tubular acidosis in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RENAL ROLE IN ACID-BASE BALANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to discussing renal tubular acidosis, it is helpful to briefly review the kidneys' role in the maintenance of acid-base balance and how disturbances in tubular function can result in metabolic acidosis. To maintain acid-base balance, the kidneys reclaim the filtered bicarbonate and excrete the daily acid load, which is primarily derived from the metabolism of sulfur-containing amino acids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Reclaiming filtered bicarbonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the bicarbonate that is filtered by the glomerulus returns to the circulation, predominately as a result of Na-H exchange by the proximal tubules. Approximately 85 to 90 percent of the filtered load is reclaimed at this site. By comparison, 10 percent is reclaimed in the distal nephron, primarily via hydrogen secretion by a proton pump (H-ATPase). Under normal conditions, there is virtually no bicarbonate in the final urine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=see_link\">",
"     \"Chapter 11A: Renal hydrogen excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proximal (type 2) RTA originates from a partial impairment in the ability of the proximal tubule to reclaim filtered bicarbonate. This defect leads to an increase in delivery of bicarbonate to the distal nephron. Since the distal nephron is initially overwhelmed, bicarbonate leaks into the final urine, leading to fall in serum bicarbonate and metabolic acidosis. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Proximal (type 2) RTA'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acid excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The excretion of the daily hydrogen ion load is primarily a function of the collecting tubules. The average daily acid load on a typical Western diet is approximately 1",
"    <span class=\"nowrap\">",
"     meq/kg.",
"    </span>",
"    In order for this acid load to be excreted in the urine, there must be buffers in the tubular lumen to bind free hydrogen ions. If hydrogen ions were free and not buffered in the urine, the daily excretion of 50 to 70 meq of acid in one liter of urine would result in a urine pH of less than 2.5 and a gradient between the cell interior and the tubular lumen of 100,000 to 1. Such a gradient cannot be achieved by the tubular cell since the minimum urine pH in humans is 4.5 to 5.0. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10089?source=see_link\">",
"     \"Chapter 11B: Regulation of renal hydrogen excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The principal buffers in the urine are ammonia (excreted and measured as ammonium) and phosphate (referred to and measured as titratable acidity). Ammonium excretion requires the renal synthesis of ammonia and the secretion of hydrogen ions from the collecting tubular cells into the tubular lumen where they are trapped as ammonium (NH4+). Ammonia [NH3] diffuses freely across membranes, while ammonium does not.",
"   </p>",
"   <p>",
"    The renal tubular production of ammonia is stimulated by intracellular acidosis. When the systemic acid load is modestly increased, near normal balance is maintained by increases in ammonium production and excretion (",
"    <a class=\"graphic graphic_figure graphicRef80366 \" href=\"UTD.htm?7/46/7917\">",
"     figure 1",
"    </a>",
"    ). Failure to excrete sufficient ammonium leads to the net retention of hydrogen ions and the development of metabolic acidosis.",
"   </p>",
"   <p>",
"    Defects in the ability to secrete either ammonium or hydrogen ions can cause metabolic acidosis. Impaired hydrogen ion secretion is the primary defect in distal RTA while impaired ammoniagenesis is the primary defect in hypoaldosteronism (type 4 RTA) and renal failure. These disorders are associated with different abnormalities in potassium balance: distal RTA is usually characterized by hypokalemia, whereas hypoaldosteronism and, in the late stages, renal failure are associated with hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All types of RTA present with a normal anion gap (hyperchloremic) metabolic acidosis. Because of their differing pathogeneses, the degree of acidosis varies with the type of RTA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In distal (type 1) RTA, there is an inability to excrete the daily acid load resulting, in the absence of alkali therapy, in progressive hydrogen ion retention and plasma bicarbonate concentration that can fall below 10",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      The urine pH is persistently 5.5 or higher, while patients with metabolic acidosis not due to RTA have a urine pH that is 5.3 or less.",
"     </li>",
"     <li>",
"      In proximal (type 2) RTA, bicarbonate wasting occurs when the plasma bicarbonate concentration is above the abnormally reduced bicarbonate reabsorptive threshold. Since the more distal segments have a substantial ability to reclaim filtered bicarbonate that escapes the proximal tubule, the plasma bicarbonate concentration is usually between 12 and 20",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in untreated patients. The urine pH is variable and, in contrast to distal RTA, is usually appropriately low (5.3 or less) in untreated patients.",
"     </li>",
"     <li>",
"      In hypoaldosteronism (type 4 RTA), the most prominent abnormality is hyperkalemia. The degree of acidosis is generally mild with the plasma bicarbonate concentration being above 17",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROXIMAL (TYPE 2) RTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal (type 2) RTA can present as an isolated defect or in association with generalized proximal tubular dysfunction called the Fanconi syndrome. In addition to bicarbonaturia, one or more of the following may be present: glucosuria, phosphaturia that can lead to hypophosphatemia, uricosuria that can lead to hypouricemia, aminoaciduria, and tubular proteinuria.",
"   </p>",
"   <p>",
"    The most common cause of proximal RTA with or without Fanconi syndrome in adults is the excretion of monoclonal light chains. This may be due to a monoclonal gammopathy or to more overt multiple myeloma. Thus, monoclonal gammopathy should be excluded in all adults with proximal RTA unless another cause is apparent. Other causes include the use of a carbonic anhydrase inhibitor such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    (which produce only bicarbonate wasting),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef68165 \" href=\"UTD.htm?22/4/22604\">",
"     table 2",
"    </a>",
"    ). In children, inherited diseases are most often responsible for proximal RTA, which is associated with the Fanconi syndrome in almost all patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link&amp;anchor=H12#H12\">",
"     \"Types of renal disease in multiple myeloma\", section on 'Renal tubular dysfunction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link&amp;anchor=H4#H4\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Proximal (type 2) RTA'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17768?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and clinical manifestations of renal tubular acidosis in infants and children\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with proximal RTA have a reduced capacity to reclaim filtered bicarbonate. Suppose, for example, that a patient with proximal RTA will be able to completely reclaim filtered bicarbonate if the plasma bicarbonate concentration is 16",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    but, if the plasma bicarbonate is above this level, bicarbonate appears in the urine. This example illustrates why, in proximal RTA, the urine pH is variable and dependent upon whether the patient is being treated with alkali therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Untreated patients with proximal RTA are in acid-base balance once the plasma bicarbonate concentration has fallen sufficiently (to 16",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in the above example) so that all of the filtered bicarbonate can be reclaimed, as occurs in individuals without proximal RTA. In this setting, the urine pH is appropriately 5.3 or less and the daily acid load is normally excreted. Thus, the fall in plasma bicarbonate is self-limited.",
"     </li>",
"     <li>",
"      In patients given alkali therapy for diagnosis or treatment, the urine pH will be inappropriately high once the plasma bicarbonate concentration is higher than the reduced reabsorptive threshold (eg, 16",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      since the filtered bicarbonate load will exceed the reduced reabsorptive capacity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of proximal RTA is made by measurement of the urine pH and fractional bicarbonate excretion during a bicarbonate infusion. The hallmark is a urine pH above 7.5 and the appearance of more than 15 percent of the filtered bicarbonate in the urine when the serum bicarbonate concentration is raised to a normal level. Patients with proximal RTA should be evaluated for Fanconi syndrome with serum and urine measurements looking for renal glycosuria, hypophosphatemia, and hypouricemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link&amp;anchor=H4#H4\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Proximal (type 2) RTA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The principal complications of the Fanconi syndrome are poor growth in children and osteomalacia in patients with hypophosphatemia due to proximal phosphate wasting. Treatment may be difficult since raising the bicarbonate concentration leads to a marked bicarbonate diuresis and excessive potassium losses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10759/abstract/5\">",
"     5",
"    </a>",
"    ]. Most children require 10 to 15",
"    <span class=\"nowrap\">",
"     meq/kg",
"    </span>",
"    of bicarbonate per day to maintain a normal pH. Treatment of mild acidosis may not be necessary in adults who are not growing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5860?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Proximal (type 2) RTA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DISTAL (TYPE 1) RTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal (type 1) RTA is characterized by an impaired capacity for hydrogen ion and therefore ammonium secretion in the collecting tubules. The impairment in hydrogen ion secretion is manifested as an abnormally high urine pH (5.5 or higher) during systemic acidosis.",
"   </p>",
"   <p>",
"    Distal RTA results from one of several defects in distal hydrogen ion secretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\", section on 'Distal (type 1) RTA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased proton pump (H-ATPase) activity",
"     </li>",
"     <li>",
"      Increased luminal membrane permeability with backleak of hydrogen ions",
"     </li>",
"     <li>",
"      Diminished distal tubular sodium reabsorption which reduces the electrical gradient for proton secretion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The causes of distal RTA are listed in the following table (",
"    <a class=\"graphic graphic_table graphicRef56437 \" href=\"UTD.htm?17/48/18188\">",
"     table 3",
"    </a>",
"    ). The most common causes in adults are autoimmune disorders and other conditions associated with chronic hyperglobulinemia. In children, distal RTA is most often a primary, hereditary condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Distal (type 1) RTA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with distal RTA present with a normal anion gap (hyperchloremic) metabolic acidosis and an inappropriately high urine pH (5.5 or higher) that cannot be attributed to infection. It is often associated with hypercalciuria due to the effects of chronic acidosis on both bone resorption and the renal tubular reabsorption of calcium. Both hypercalciuria and especially hypocitraturia contribute to the development of nephrolithiasis and nephrocalcinosis, a not uncommon complication of this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10759/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23973?source=see_link\">",
"     \"Nephrolithiasis in renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypokalemia, sometimes severe, is frequently seen in distal RTA and may produce muscle weakness. How this occurs is not well understood [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10759/abstract/7\">",
"     7",
"    </a>",
"    ]. Potassium wasting with a proton pump defect is in part related to the reduction in distal hydrogen secretion. In this setting, potassium secretion must be enhanced to maintain electroneutrality as sodium is reabsorbed.",
"   </p>",
"   <p>",
"    The effect on potassium balance is different when distal RTA is due to the third mechanism listed above, impaired sodium reabsorption. In this setting, which most often occurs with urinary tract obstruction or sickle cell disease, the defect in sodium reabsorption interferes with both potassium and hydrogen ion secretion and hyperkalemia may be observed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10759/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\", section on 'Distal (type 1) RTA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Correction of the acidosis with alkali therapy (usually potassium citrate) generally improves both calcium and potassium balance, and prevents stones and nephrocalcinosis. In contrast to the high alkali requirement in proximal RTA, only the daily acid load (1 to 2",
"    <span class=\"nowrap\">",
"     meq/kg",
"    </span>",
"    per day) has to be replenished with alkali therapy in distal RTA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5860?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis\", section on 'Distal (type 1) RTA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Incomplete distal RTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the incomplete form of distal RTA have a persistently high urine pH and hypocitraturia, as in the complete form, but are able to maintain net acid excretion and the plasma bicarbonate concentration in the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10759/abstract/9\">",
"     9",
"    </a>",
"    ]. The pathogenesis of this disorder is not well understood. These patients can develop hypercalciuria, hypocitraturia, and nephrolithiasis, and treatment with alkali therapy may ameliorate stone formation. Thus, incomplete distal RTA should be considered in any calcium stone former with a urine pH persistently 5.5 or higher in the absence of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\", section on 'Incomplete distal RTA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HYPOALDOSTERONISM (TYPE 4 RTA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoaldosteronism (type 4 RTA) is due to either aldosterone deficiency or tubular resistance to the action of aldosterone (",
"    <a class=\"graphic graphic_table graphicRef82440 \" href=\"UTD.htm?41/0/41995\">",
"     table 4",
"    </a>",
"    ). The most common form of aldosterone deficiency in adults is hyporeninemic hypoaldosteronism which is frequently observed among patients with mild to moderate chronic kidney disease, especially if due to diabetic nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10759/abstract/10\">",
"     10",
"    </a>",
"    ]. Adrenal insufficiency and, in children, some forms of congenital adrenal hyperplasia are other common causes of hypoaldosteronism. Resistance to the action of aldosterone is observed in patients with chronic tubulointerstitial disease, those treated with potassium-sparing diuretics, and rare congenital disorders called pseudohypoaldosteronism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since aldosterone is the major hormone that promotes potassium excretion, hyperkalemia is the primary electrolyte abnormality among patients with hypoaldosteronism. The disorder is typically associated with a mild metabolic acidosis that may be due to suppression of ammonia excretion by hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10759/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with hypoaldosteronism typically have an appropriately acid urine pH (5.3 or less in the presence of acidosis) and a plasma bicarbonate concentration above 17",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    The diagnosis can be made by measurement of plasma renin and aldosterone levels but many patients are treated empirically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link\">",
"     \"Causes and evaluation of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     Fludrocortisone",
"    </a>",
"    is effective in managing the hyperkalemia associated with aldosterone deficiency. However, it is not often utilized because hypertension, heart failure, and edema may be exacerbated in these patients who typically have renal insufficiency. Most patients can be effectively managed with restriction of dietary potassium and, if necessary, diuretics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link&amp;anchor=H15#H15\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CHRONIC KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients with moderate to severe chronic kidney disease, there is a high anion gap acidosis rather than the normal gap acidosis characteristic of distal RTA. This discrepancy is not due to a difference in the etiology of the acidosis, since the proximate cause is impairment in ammonium excretion in both disorders.",
"   </p>",
"   <p>",
"    As the number of functioning nephrons declines in patients with chronic kidney disease, net acid excretion is initially maintained by increased ammonium excretion per nephron. However, total ammonium excretion begins to fall when the glomerular filtration rate is below 40 to 50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    At this time, ammonium excretion per total glomerular filtration rate is three to four times above normal, suggesting that the impairment in ammonium excretion is due to too few functioning nephrons rather than impaired function in the remaining nephrons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=see_link&amp;anchor=H1#H1\">",
"     \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\", section on 'Acid-base balance in chronic kidney disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The net effect is an increasing tendency to the net retention of hydrogen ions, which can lead to a progressive metabolic acidosis. The anion gap is usually, but not always, elevated in this setting due to the concomitant retention of anions such as phosphate, sulfate, urate, and hippurate resulting from the reduced glomerular filtration rate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10759/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients who have a normal anion gap can be distinguished from those with distal RTA by the elevated serum creatinine and a urine pH of 5.3 or less.",
"   </p>",
"   <p>",
"    The indications for treatment of metabolic acidosis in patients with chronic kidney disease are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\", section on 'Treatment of metabolic acidosis in CKD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6893608\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term \"renal tubular acidosis\" (RTA) refers to a group of disorders in which, despite a relatively well-preserved glomerular filtration rate, metabolic acidosis develops because of defects in the ability of the renal tubules to perform the normal functions required to maintain acid-base balance. All forms of RTA are characterized by a normal anion gap (hyperchloremic) metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three major subgroups of RTA with different clinical characteristics (",
"      <a class=\"graphic graphic_table graphicRef58428 \" href=\"UTD.htm?22/42/23211\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Distal or type 1 RTA",
"     </li>",
"     <li>",
"      Proximal or type 2 RTA",
"     </li>",
"     <li>",
"      Hypoaldosteronism or type 4 RTA",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proximal tubule reclaims 85 to 90 percent of filtered bicarbonate, primarily by Na-H exchange. The remaining 10 percent is reclaimed in the distal nephron. Under normal conditions, there is virtually no bicarbonate in the final urine. Proximal (type 2) RTA originates from a partial impairment in the ability of the proximal tubule to reclaim filtered bicarbonate. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Reclaiming filtered bicarbonate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The average daily acid load on a typical Western diet is approximately 1",
"      <span class=\"nowrap\">",
"       meq/kg.",
"      </span>",
"      In order for this acid load to be excreted in the urine, there must be buffers to bind free hydrogen ions. The principal buffers in the urine are ammonia and phosphate. Ammonium excretion requires the renal synthesis of ammonia and the secretion of hydrogen ions from the collecting tubular cells into the tubular lumen where they are trapped as ammonium (NH4+). Failure to excrete sufficient ammonium leads to the net retention of hydrogen ions and the development of metabolic acidosis. Impaired hydrogen ion secretion is the primary defect in distal (type 1) RTA while impaired ammoniagenesis is the primary defect in hypoaldosteronism (type 4 RTA) and renal failure. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Acid excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proximal (type 2) RTA can present as an isolated defect or in association with generalized proximal tubular dysfunction called the Fanconi syndrome. The most common causes of proximal RTA with or without Fanconi syndrome in adults are the excretion of light chains due to monoclonal gammopathy (",
"      <a class=\"graphic graphic_table graphicRef68165 \" href=\"UTD.htm?22/4/22604\">",
"       table 2",
"      </a>",
"      ). Patients with proximal RTA have a reduced capacity to reclaim filtered bicarbonate, usually presenting with a serum bicarbonate of approximately 16",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      with a variable urine pH, depending upon whether the patient is being treated with alkali therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Proximal (type 2) RTA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Distal (type 1) RTA is characterized by an impaired capacity for hydrogen ion and therefore ammonium secretion in the collecting tubules. The impairment in hydrogen ion secretion is manifested as an abnormally high urine pH (5.5 or higher) and a serum bicarbonate that can be below 10",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Distal RTA results from one of several defects in distal hydrogen ion secretion (",
"      <a class=\"graphic graphic_table graphicRef56437 \" href=\"UTD.htm?17/48/18188\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Distal (type 1) RTA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypoaldosteronism (type 4 RTA) is due to either aldosterone deficiency or tubular resistance to the action of aldosterone (",
"      <a class=\"graphic graphic_table graphicRef82440 \" href=\"UTD.htm?41/0/41995\">",
"       table 4",
"      </a>",
"      ). Since aldosterone is the major hormone that promotes potassium excretion, hyperkalemia is the primary electrolyte abnormality among patients with hypoaldosteronism. The disorder is typically associated with a mild metabolic acidosis (a serum bicarbonate concentration typically above 17",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      and an appropriately acid urine pH. The acidosis may be due to suppression of ammonia excretion by hyperkalemia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hypoaldosteronism (type 4 RTA)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most patients with chronic kidney disease, net acid excretion is initially maintained by increased ammonium excretion per nephron. However, total ammonium excretion begins to fall when the glomerular filtration rate is below 40 to 50",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      reflecting too few functioning nephrons to adequately excrete the acid load. The net effect is a progressive metabolic acidosis. The anion gap is usually, but not always, elevated in this setting due to the concomitant retention of anions such as phosphate, sulfate, urate, and hippurate. Patients who have a normal anion gap can be distinguished from those with distal RTA by the elevated serum creatinine and a urine pH of 5.3 or less. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chronic kidney disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10759/abstract/1\">",
"      Rodr&iacute;guez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol 2002; 13:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10759/abstract/2\">",
"      Gluck SL. Acid-base. Lancet 1998; 352:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10759/abstract/3\">",
"      Sly WS, Whyte MP, Sundaram V, et al. Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. N Engl J Med 1985; 313:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10759/abstract/4\">",
"      Hu PY, Roth DE, Skaggs LA, et al. A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arabic countries. Hum Mutat 1992; 1:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10759/abstract/5\">",
"      Sebastian A, McSherry E, Morris RC Jr. Renal potassium wasting in renal tubular acidosis (RTA): its occurrence in types 1 and 2 RTA despite sustained correction of systemic acidosis. J Clin Invest 1971; 50:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10759/abstract/6\">",
"      Brenner RJ, Spring DB, Sebastian A, et al. Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis. N Engl J Med 1982; 307:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10759/abstract/7\">",
"      Batlle D, Moorthi KM, Schlueter W, Kurtzman N. Distal renal tubular acidosis and the potassium enigma. Semin Nephrol 2006; 26:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10759/abstract/8\">",
"      Batlle DC, Arruda JA, Kurtzman NA. Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. N Engl J Med 1981; 304:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10759/abstract/9\">",
"      Buckalew VM Jr, McCurdy DK, Ludwig GD, et al. Incomplete renal tubular acidosis. Physiologic studies in three patients with a defect in lowering urine pH. Am J Med 1968; 45:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10759/abstract/10\">",
"      DeFronzo RA. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 1980; 17:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10759/abstract/11\">",
"      Widmer B, Gerhardt RE, Harrington JT, Cohen JJ. Serum electrolyte and acid base composition. The influence of graded degrees of chronic renal failure. Arch Intern Med 1979; 139:1099.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2366 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10759=[""].join("\n");
var outline_f10_32_10759=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6893608\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RENAL ROLE IN ACID-BASE BALANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Reclaiming filtered bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acid excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROXIMAL (TYPE 2) RTA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DISTAL (TYPE 1) RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Incomplete distal RTA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HYPOALDOSTERONISM (TYPE 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6893608\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2366\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2366|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/46/7917\" title=\"figure 1\">",
"      Acid load and NH4 excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2366|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/42/23211\" title=\"table 1\">",
"      Characteristics of RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/4/22604\" title=\"table 2\">",
"      Major causes of type 2 RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/48/18188\" title=\"table 3\">",
"      Major causes of type 1 RTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/0/41995\" title=\"table 4\">",
"      Major causes of hypoaldosteronism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12762?source=related_link\">",
"      Chapter 11A: Renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10089?source=related_link\">",
"      Chapter 11B: Regulation of renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17768?source=related_link\">",
"      Etiology and clinical manifestations of renal tubular acidosis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23973?source=related_link\">",
"      Nephrolithiasis in renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=related_link\">",
"      Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5860?source=related_link\">",
"      Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=related_link\">",
"      Types of renal disease in multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_32_10760="Treatment of dyslipidemia in the older adult";
var content_f10_32_10760=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of dyslipidemia in the older adult",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/32/10760/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10760/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/32/10760/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10760/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10760/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/32/10760/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10760/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/32/10760/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials of cholesterol lowering therapies have demonstrated consistent near-term benefits for patients with established coronary heart disease (CHD) and long-term benefits for those with severe hypercholesterolemia who are currently free of clinical CHD (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    ). Unfortunately, these trials have typically excluded older patients.",
"   </p>",
"   <p>",
"    The bias against older individuals stems from illusory concerns regarding life expectancy, comorbidity, safety of lipid lowering agents, and cost-benefit analysis of preventive care in older adults. In fact, the absolute risk for CHD increases dramatically with age in both men and women (",
"    <a class=\"graphic graphic_figure graphicRef77317 \" href=\"UTD.htm?29/58/30637\">",
"     figure 1",
"    </a>",
"    ). Thus, the absolute number of persons benefiting from cholesterol lowering should be greater in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR DISEASE IN OLDER ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large proportion of older individuals will suffer from CHD. In men over the age of 65, for example, nearly one-half of all deaths are attributed to CHD, compared to less than 25 percent for all cancers and less than 2 percent for all infections. An even higher proportion of deaths are due to CHD in older women (56 percent) with less than 20 percent being due to cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Age-related changes in lipoprotein metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longitudinal studies have shown that total cholesterol levels increase in males after the onset of puberty until age 50. This is followed by a plateau until age 70, with the serum cholesterol concentration then falling slightly. Although it has been suspected that the latter change may be an artifact resulting from CHD deaths in hypercholesterolemic men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/3\">",
"     3",
"    </a>",
"    ], the most important factor influencing cholesterol may be weight change [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/4\">",
"     4",
"    </a>",
"    ]. The reduction in total and LDL cholesterol and the increase in HDL-cholesterol in older men, primarily occur in those who lost weight, while age is not a factor.",
"   </p>",
"   <p>",
"    In women, the serum cholesterol concentration is slightly higher than in men prior to age 20 to 25. Between the ages of 25 to 55, the serum cholesterol rises although at a slower incremental rate than in men. Cholesterol levels in women are equal to those of men between the ages of 55 to 60 and exceed those in men in older age groups.",
"   </p>",
"   <p>",
"    The age-related changes in the serum cholesterol concentration primarily result from an increase in LDL-cholesterol (",
"    <a class=\"graphic graphic_figure graphicRef61522 \" href=\"UTD.htm?29/54/30573\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/3\">",
"     3",
"    </a>",
"    ]. In comparison, HDL-cholesterol levels do not vary much with age, being about 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.26",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    higher in women than men.",
"   </p>",
"   <p>",
"    The mechanisms responsible for the progressive age-related elevation in LDL-cholesterol have not been fully explained; however, the data support a primary role for a decrease in the fractional catabolic rate of LDL-cholesterol. This reduction in LDL catabolism is thought to result from diminished activity of hepatic LDL receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cholesterol as a predictor of cardiovascular risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between hypercholesterolemia and CHD in elderly men and women has been demonstrated in a number of large series [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. In the Framingham Heart Study, for example, the relative risk of developing symptomatic CHD was 1.5 in men and 2.3 in women with a total cholesterol level at the 90th percentile when compared to those with a plasma cholesterol concentration below 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/6\">",
"     6",
"    </a>",
"    ]. These findings have been confirmed in almost all other major epidemiologic studies of older men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The relative risk for CHD varied between 1.5 and 1.65 for subjects with a total cholesterol level in the upper quartile or upper 10 percent.",
"   </p>",
"   <p>",
"    Low HDL cholesterol is also a risk factor. This was illustrated in a prospective cohort study of 2,527 women and 1,377 men which examined the effect of total cholesterol and HDL cholesterol on the CHD death rate in persons over age 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/12\">",
"     12",
"    </a>",
"    ]. At a follow-up of 4.4 years, an elevated total cholesterol concentration (&gt;240",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 6.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    was significantly correlated with CHD mortality in women (relative risk = 1.8) but not in men (relative risk = 1.1). The relative risk of coronary mortality for those with low HDL levels (&lt;35",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 0.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    was 4.9 in men and 2.0 in women. The Framingham Heart Study and the Systolic Hypertension in the Elderly Program (SHEP) also found that both high LDL and low HDL-cholesterol levels were significant CHD risk factors in elderly subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/6,10\">",
"     6,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some reports have observed a U- or J-shaped curve in the elderly in which lower cholesterol levels are paradoxically associated with an increase in cardiovascular risk. In a longitudinal study of 4066 elderly men and women, for example, death from coronary heart disease increased at serum cholesterol levels below 160",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/13\">",
"     13",
"    </a>",
"    ]. If, however, adjustments were made for CHD risk factors and for serum iron and albumin (to account for comorbid disease and frailty), the increase in risk at lower cholesterol values disappeared.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Relative risk versus attributable risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;In assessing the importance of the relation between cholesterol and CHD in the elderly and the potential value of hypolipidemic therapy, it is critical to distinguish between relative risk and attributable or absolute risk. The relative risk or risk ratio is the ratio of disease prevalence in one population without the risk factor to the risk in another population possessing the risk factor. The attributable risk is the absolute difference in disease prevalence between the two groups. Suppose, for example, that the incidence of CHD at five years is 20 percent in hypercholesterolemic subjects and 12 percent in subjects with normal cholesterol levels. The relative risk for CHD in hypercholesterolemia in this setting is 1.67 (20 &divide; 12) while the attributable risk is 8 percent, meaning that eight out of every 100 hypercholesterolemic patients will have a coronary event not seen in those with a normal plasma cholesterol concentration.",
"   </p>",
"   <p>",
"    The relative risk or risk ratio is a good measure of the strength of an association in assessing causality. Use of the risk ratio was valuable in early analyses because a significantly elevated risk ratio implied causality and strengthened the argument that elevated serum cholesterol levels are causally linked to CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the attributable risk is a more useful clinical measurement, since it estimates how much elevated cholesterol levels contribute to coronary heart disease. It also estimates how much the risk might be reduced if the hypercholesterolemia were corrected [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/15\">",
"     15",
"    </a>",
"    ]. Because CHD morbidity and mortality rates increase with age, the attributable risk of high total cholesterol is greater in the elderly even though the relative risk decreases with age (ie, a smaller percentage of a larger number of events results in a larger increase in absolute risk) (",
"    <a class=\"graphic graphic_figure graphicRef63524 \" href=\"UTD.htm?19/51/20285\">",
"     figure 3",
"    </a>",
"    ). The increase in absolute risk in the elderly suggests that the benefit from cholesterol-lowering therapy should be greater than in younger individuals. This point, although not widely appreciated, has important implications for treating hypercholesterolemia in the elderly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BENEFITS OF LIPID LOWERING LIPID IN THE ELDERLY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The secondary prevention trials of LDL-cholesterol lowering therapies have shown a reduction in cardiac events and all cause mortality (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    ). However, these studies had only limited data in older subjects. Nevertheless, subgroup analysis of trials that included elderly individuals suggests that they have a similar benefit from lipid lowering therapy as younger subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/2,16-21\">",
"     2,16-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Scandinavian",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       Simvastatin",
"      </a>",
"      Survival Study (4S trial) included 1021 patients greater than 65 years of age with angina or a previous myocardial infarction and hypercholesterolemia (baseline plasma total cholesterol levels between 212 and 309",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [5.5 and 8.0",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/16\">",
"       16",
"      </a>",
"      ]. Similar reductions in serum lipids were observed among elderly and younger individuals. In the older patients, treatment with simvastatin reduced all cause mortality (34 percent lower), mortality from coronary heart disease (43 percent), major coronary events (34 percent), and the number of revascularization procedures (41 percent).",
"     </li>",
"     <li>",
"      The Cholesterol and Recurrent Events (CARE) trial included 1283 patients between the ages of 65 and 75 who had average levels of total, LDL and HDL cholesterol of 209",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      139",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      and 39",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.4, 3.6, and 1.0",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/18\">",
"       18",
"      </a>",
"      ]. Reductions in coronary events were similar to the 4S trial (",
"      <a class=\"graphic graphic_figure graphicRef81441 \" href=\"UTD.htm?11/62/12270\">",
"       figure 4",
"      </a>",
"      ). It was estimated that for every 1000 older patients treated, 225 cardiovascular hospitalizations and 207 cardiovascular events would be prevented compared with 121 hospitalizations and 150 cardiovascular events in 1000 younger patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The LIPID trial included 3514 patients between the ages of 65 and 75 years who had a prior infarction or unstable angina in addition to a baseline serum cholesterol of 155 to 271",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4 to 7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/20\">",
"       20",
"      </a>",
"      ]. Although the risk of all cardiovascular events and all-cause mortality were reduced by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      therapy to a similar degree in older and younger patients, the absolute benefit was greater in the elderly because of a greater risk for these events; fewer elderly patients needed to be treated to prevent one death from any cause (22 versus 46 for younger patients), one death from CHD (35 versus 71), one cardiovascular death (28 versus 61), one fatal or nonfatal MI (30 versus 36), or one stroke (79 versus 170).",
"     </li>",
"     <li>",
"      The Heart Protection Study included over 20,000 patients with varying lipid profiles (33 percent had baseline LDL cholesterol &lt;116",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [&lt;3",
"      <span class=\"nowrap\">",
"       mmol/L],",
"      </span>",
"      25 percent had a level of 116 to 135",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3 to 3.5",
"      <span class=\"nowrap\">",
"       mmol/L],",
"      </span>",
"      and 42 percent had levels &gt;135",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [&gt;3.5",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/21\">",
"       21",
"      </a>",
"      ]. Entry criteria were age 40 to 80 years, a history of cardiovascular disease (coronary cerebrovascular, or peripheral vascular disease), diabetes mellitus, or treated hypertension. Thus, most patients were treated for secondary prevention. Treatment with simvastatin was associated with a reduction in cardiovascular events that was similar in patients above and below age 65. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H28#H28\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'Heart Protection Study'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Similarly, in the CARDS study in patients with type 2 diabetes without known CHD,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      10 mg daily reduced first major cardiovascular events by 37 percent in patients younger than 65 and by 38 percent in patients 65 and older [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the TNT (Treating to New Targets) study,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      80 mg versus 10 mg in 10,001 patients with stable CHD significantly decreased the risk for major cardiovascular events in those both ages 65 and older (n = 3809) and in younger patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H20#H20\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'TNT trial'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in an analysis of pooled data from three randomized trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    involving 19,768 patients (CARE, LIPID, and WOSCOPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/25\">",
"     25",
"    </a>",
"    ]; two of these are discussed individually above. The relative reduction in the risk of cardiac events was comparable for patients ages &lt;55 years, 55 to 64 years, and 65 to 75 years (32, 21, and 26, respectively).",
"   </p>",
"   <p>",
"    Subgroup analyses from primary prevention trials of statins, including",
"    <span class=\"nowrap\">",
"     AFCAPS/TexCAPS,",
"    </span>",
"    and ASCOT-LLA found similar relative effects of therapy on clinical endpoints in younger and older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. In JUPITER, a large trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    in patients with low-to-average LDL-C levels and elevated c-reactive protein levels, although the relative risk reductions were similar in older and younger patients, the absolute reduction in the primary composite cardiovascular endpoint was 0.77 events per 100 patient-years in the 5695 patients ages 70 and older, which was greater than the reduction of 0.52 events per 100 patient-years seen in the 12,107 patients ages 50 to 69 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies that specifically included older adult patients add further evidence that treatment of hypercholesterolemia in older adults provides similar benefits to that of treatment in younger people [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PROSPER trial randomly assigned 5804 men and women ages 70 to 82 years with a history of or risk factors for vascular disease to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      (40 mg per day) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/30\">",
"       30",
"      </a>",
"      ]. During a mean follow-up of only three years, pravastatin treatment was associated with both significantly lower LDL concentrations and a significantly reduced risk of the primary end point (coronary death, nonfatal myocardial infarction, and fatal or nonfatal stroke, hazard ratio [HR] 0.81, 95% CI 0.74-0.97). Stroke risk alone was unaffected by therapy, but pravastatin was associated with significantly lower risk of coronary death and nonfatal myocardial infarction. There was, however, no significant reduction in all-cause mortality (HR 0.97, CI 0.83-1.14), and there was a significant increase in new diagnoses of cancer (HR 1.25, CI 1.04-1.51). The authors performed a meta-analysis of statin trials including PROSPER and found no overall evidence of an increased risk of cancer with statins (HR 1.02, CI 0.96-1.09). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link&amp;anchor=H11#H11\">",
"       \"Statins: Actions, side effects, and administration\", section on 'Side effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The SAGE trial compared intensive and moderate statin therapy in patients with known CHD ages 65 to 85 who had at least one episode of ischemia on baseline screening with 48-hour ambulatory monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/31\">",
"       31",
"      </a>",
"      ]. Patients were randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      80 mg daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      40 mg daily. There was no difference between the two groups in the primary endpoint of duration of ischemia on ambulatory monitoring at month 12. However, there was a trend toward a reduction in a composite endpoint of major cardiovascular events with intensive therapy (HR 0.71, CI 0.46-1.09), and a post-hoc analysis found a reduction in mortality (HR 0.33, CI 0.13-0.83). In contrast, no similar reduction in mortality was seen with intensive statin therapy in patients ages 65 and older (n = 3809) in the TNT trial (HR 1.08, CI 0.87-1.33) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/24,32\">",
"       24,32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H20#H20\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'TNT trial'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these apparent benefits, compliance with statin therapy declines substantially with time in older adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This occurs even when cost is not an issue. The adherence rate is similar to that observed for treatment of hypertension, another asymptomatic condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Time course for CHD benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention of CHD in elderly subjects has been hindered by the perception that LDL lowering therapy requires many years before the course of atherosclerosis can be altered. This concept has been challenged by the observation that clinical benefits are seen as early as",
"    <strong>",
"     six months to two years",
"    </strong>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef62070 \" href=\"UTD.htm?19/57/20381\">",
"     figure 5",
"    </a>",
"    ), in many cases before atherosclerosis regression has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. In addition, statin therapy can improve endothelial dysfunction within three days of initiating therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of lipid lowering agents in older subjects was evaluated in two double-blind, placebo-controlled trials that included 573 patients over the age of 64 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    was associated with a fall in cholesterol levels similar to that seen in younger subjects. There was no statistically significant difference in side effects between the treatment and placebo groups. Neither trial provided information regarding the effect of therapy on morbidity and mortality.",
"   </p>",
"   <p>",
"    An analysis from the CARDS study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    10 mg daily in patients with type 2 diabetes without known CHD found similar rates of adverse events in patients younger than age 65 and in those ages 65 and older [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/22\">",
"     22",
"    </a>",
"    ]. For both younger and older patients, the rates of adverse events were no different with atorvastatin or placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"   </p>",
"   <p>",
"    The decision whether to treat high or high-normal serum cholesterol in an elderly individual needs to be individualized, being based upon both chronological and physiologic age. As an example, a patient with a limited life span from a concomitant illness is probably not a candidate for drug therapy. On the other hand, an otherwise healthy elderly individual should not be denied drug therapy simply on the basis of age alone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The studies described above support the use of lipid lowering therapy for",
"    <strong>",
"     secondary prevention",
"    </strong>",
"    in older patients with established CHD who do not have life-limiting comorbid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/16-18,20,21\">",
"     16-18,20,21",
"    </a>",
"    ]. These patients should be treated similar to younger patients according to the guidelines established by the National Cholesterol Education Program (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. There are limited data on the value of treating elderly patients with low HDL-cholesterol (&lt;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.03",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    but again, presumably the same principles would apply as in younger patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=see_link\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison, there are more limited data concerning the use of lipid lowering for",
"    <strong>",
"     primary prevention",
"    </strong>",
"    of CHD in elderly hypercholesterolemic patients. Because of the progressive elevation in total and LDL cholesterol levels with aging (",
"    <a class=\"graphic graphic_figure graphicRef61522 \" href=\"UTD.htm?29/54/30573\">",
"     figure 2",
"    </a>",
"    ), it has been estimated 40 percent or more of those above age 65 meet the National Cholesterol Education Program guidelines for treating hypercholesterolemia (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    ) This would entail a large annual cost.",
"   </p>",
"   <p>",
"    On the other hand, over 50 percent of older individuals will eventually die from cardiovascular disease and data from the Cardiovascular Health Study suggest significant benefit from primary prevention in patients ages 65 and older [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/41\">",
"     41",
"    </a>",
"    ]. The Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III or ATP III), published before the results of the Cardiovascular Health Study were available, recommended that therapeutic lifestyle changes are the first line of primary prevention for older individuals, although LDL-cholesterol lowering drugs can be considered when older patients have multiple risk factors for CHD as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef60480 \" href=\"UTD.htm?2/16/2316\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite their proven benefit, lipid-lowering drugs are markedly underutilized in elderly patients. This was illustrated in a prospective study of 500 patients with a mean age of 81 years and a Q wave myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/42\">",
"     42",
"    </a>",
"    ]. Although 67 percent had a serum LDL-cholesterol concentration above 125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.2",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    only 5 percent were treated with a lipid-lowering drug. A retrospective cohort study of 396,077 high-risk elderly patients found that prescription of statins decreased with increasing age and also with increasing cardiovascular risk and risk of death; thus, the elderly patients likely to get the greatest absolute benefit from statins appear least likely to receive them [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10760/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ADDITIONAL ISSUES IN OLDER ADULTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Secondary causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older adult patients commonly have medical conditions that may contribute to dyslipidemia. Etiologies to consider include hypothyroidism, diabetes mellitus, and nephrotic syndrome. Therapies may also contribute to dyslipidemias. As examples, thiazide diuretics can affect lipid metabolism, and antipsychotics used for agitation in dementia can produce weight gain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43621?source=see_link\">",
"     \"Secondary causes of dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dietary modifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;While therapeutic lifestyle changes involving exercise and diet are generally the first line of treatment for dyslipidemias, providers should avoid dietary restrictions in older patients who are at high risk of malnutrition. These include patients with dementia or physical disabilities that limit their access to adequate nutrition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of dementia\", section on 'Nutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Drug interactions and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients are frequently treated with multiple medications and so are at increased risk for complications of drug interactions. As an example, macrolide antibiotics can raise statin levels and thus the risk of muscle toxicity (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    ). Providers should be particularly cautious of such interactions in older patients.",
"   </p>",
"   <p>",
"    Additionally, older adult patients may have greater susceptibility to medication side effects, such as bloating and constipation with bile acid sequestrants, and hyperglycemia and gout with niacin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link&amp;anchor=H2#H2\">",
"     \"Lipid lowering with drugs other than statins and fibrates\", section on 'Bile acid sequestrants'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link&amp;anchor=H5#H5\">",
"     \"Lipid lowering with drugs other than statins and fibrates\", section on 'Nicotinic acid (Niacin)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8922241\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary heart disease (CHD) is the most common cause of death in older patients, and, as in younger patients, dyslipidemia is associated with an increased risk of CHD. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cardiovascular disease in older adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the relative risk of hypercholesterolemia is somewhat lower in older patients, the absolute risk is higher than in younger patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Relative risk versus attributable risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The relative benefit of lipid lowering therapy in older patients is similar to that in younger patients, and the absolute benefit is typically greater than in younger patients. Particularly in secondary prevention, the absolute benefits are large enough that many older patients with CHD would benefit from lipid-lowering therapy, and older patients with a reasonable life expectancy may also benefit in primary prevention. Side effects of lipid lowering therapy may also be similar in older and younger patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Benefits of lipid lowering lipid in the elderly'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reductions in events with statin therapy can occur quickly (within weeks to months), and so even in older patients such therapy can be expected to reduce events during a patient&rsquo;s expected lifespan. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Time course for CHD benefit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary causes of dyslipidemia such as hypothyroidism, diabetes, nephrotic syndrome, and drug effects should be considered, particularly in older patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43621?source=see_link\">",
"       \"Secondary causes of dyslipidemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/1\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/2\">",
"      Grundy SM, Cleeman JI, Rifkind BM, Kuller LH. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med 1999; 159:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/3\">",
"      Kreisberg RA, Kasim S. Cholesterol metabolism and aging. Am J Med 1987; 82:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/4\">",
"      Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation 1997; 96:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/5\">",
"      Ericsson S, Eriksson M, Vitols S, et al. Influence of age on the metabolism of plasma low density lipoproteins in healthy males. J Clin Invest 1991; 87:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/6\">",
"      Castelli WP, Wilson PW, Levy D, Anderson K. Cardiovascular risk factors in the elderly. Am J Cardiol 1989; 63:12H.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/7\">",
"      Benfante R, Reed D. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA 1990; 263:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/8\">",
"      Agner E, Hansen PF. Fasting serum cholesterol and triglycerides in a ten-year prospective study in old age. Acta Med Scand 1983; 214:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/9\">",
"      Rubin SM, Sidney S, Black DM, et al. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med 1990; 113:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/10\">",
"      Frost PH, Davis BR, Burlando AJ, et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation 1996; 94:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/11\">",
"      Houterman S, Verschuren WM, Hofman A, Witteman JC. Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam Study. J Intern Med 1999; 246:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/12\">",
"      Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995; 274:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/13\">",
"      Corti MC, Guralnik JM, Salive ME, et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med 1997; 126:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/14\">",
"      Malenka DJ, Baron JA. Cholesterol and coronary heart disease. The importance of patient-specific attributable risk. Arch Intern Med 1988; 148:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/15\">",
"      Gordon DJ, Rifkind BM. Treating high blood cholesterol in the older patient. Am J Cardiol 1989; 63:48H.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/16\">",
"      Miettinen TA, Py&ouml;r&auml;l&auml; K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96:4211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/17\">",
"      Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995; 92:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/18\">",
"      Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/19\">",
"      LaRosa JC. Prevention and treatment of coronary heart disease: who benefits? Circulation 2001; 104:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/20\">",
"      Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001; 134:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/21\">",
"      Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/22\">",
"      Neil HA, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 2006; 29:2378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/23\">",
"      Wenger NK, Lewis SJ, Herrington DM, et al. Effect of 80 mg versus 10 mg of atorvastatin in patients &ge; and &lt;65 years of age with stable coronary heart disease. Circulation 2005; 112:II.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/24\">",
"      Wenger NK, Lewis SJ, Herrington DM, et al. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007; 147:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/25\">",
"      Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000; 102:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/26\">",
"      Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/27\">",
"      Sever PS, Dahl&ouml;f B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/28\">",
"      Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 2010; 152:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/29\">",
"      Allen Maycock CA, Muhlestein JB, Horne BD, et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol 2002; 40:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/30\">",
"      Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/31\">",
"      Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007; 115:700.",
"     </a>",
"    </li>",
"    <li>",
"     Wenger, NK. Personal communication (July 9, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/33\">",
"      Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/34\">",
"      Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/35\">",
"      Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/36\">",
"      Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993; 72:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/37\">",
"      Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/38\">",
"      Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/39\">",
"      LaRosa JC, Applegate W, Crouse JR 3rd, et al. Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study. Arch Intern Med 1994; 154:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/40\">",
"      Santinga JT, Rosman HS, Rubenfire M, et al. Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia. Am J Med 1994; 96:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/41\">",
"      Lemaitre RN, Psaty BM, Heckbert SR, et al. Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med 2002; 162:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/42\">",
"      Aronow WS. Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol &gt; 125 mg/dl. Am J Cardiol 1998; 82:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10760/abstract/43\">",
"      Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291:1864.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4569 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-430C2FE721-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10760=[""].join("\n");
var outline_f10_32_10760=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8922241\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CARDIOVASCULAR DISEASE IN OLDER ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Age-related changes in lipoprotein metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cholesterol as a predictor of cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Relative risk versus attributable risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BENEFITS OF LIPID LOWERING LIPID IN THE ELDERLY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Time course for CHD benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ADDITIONAL ISSUES IN OLDER ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Secondary causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dietary modifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Drug interactions and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8922241\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4569\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4569|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/58/30637\" title=\"figure 1\">",
"      CHD mortality by age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/54/30573\" title=\"figure 2\">",
"      Lipid levels with aging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/51/20285\" title=\"figure 3\">",
"      Relative and attributable risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/62/12270\" title=\"figure 4\">",
"      Pravastatin outcome vs age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/57/20381\" title=\"figure 5\">",
"      Pravastatin improves CHD risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4569|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/16/2316\" title=\"table 1\">",
"      Primary prevention CHD elderly",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43621?source=related_link\">",
"      Secondary causes of dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_32_10761="Systemic therapy for advanced cholangiocarcinoma";
var content_f10_32_10761=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic therapy for advanced cholangiocarcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/32/10761/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10761/contributors\">",
"     Keith E Stuart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/32/10761/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10761/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/32/10761/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10761/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/32/10761/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholangiocarcinomas are rare malignancies arising from the epithelial cells of the intrahepatic and extrahepatic bile ducts. Systemic therapy for advanced cholangiocarcinoma will be reviewed here. Surgical and other local treatments for cholangiocarcinoma and ampullary cancer, epidemiology, pathology, classification, clinical presentation, and diagnosis of cholangiocarcinomas and ampullary cancers, and systemic therapy for gallbladder cancer are all discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/33/25114?source=see_link\">",
"     \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34728?source=see_link\">",
"     \"Treatment options for locally advanced cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43881?source=see_link\">",
"     \"Epidemiology, pathogenesis, and classification of cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=see_link\">",
"     \"Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3674?source=see_link\">",
"     \"Ampullary carcinoma: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15082?source=see_link\">",
"     \"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic chemotherapy is increasingly being applied in cases of advanced cholangiocarcinoma. A benefit for chemotherapy over best supportive care alone was suggested in a trial that randomly assigned 90 patients with advanced pancreatic or biliary cancer (37 with bile duct cancer) to 5-FU-based systemic chemotherapy or best supportive care alone (median survival 6 versus 2.5 months, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The literature regarding treatment results with specific regimens is limited because most series are small, and many reports consist of a mix of bile duct cancers, gallbladder cancer, ampullary cancer, and either pancreatic or hepatocellular cancers. Although they arise in similar locations, these cancers all have a unique natural history and response to chemotherapy. In general, no single drug or combination has consistently increased median survival beyond the expected six to eight months. The most active agents are 5-FU,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced biliary tract cancer are a heterogeneous group, comprising both locally advanced and metastatic disease, as well as a variety of primary disease sites (intrahepatic bile ducts, extrahepatic bile ducts, gallbladder, and ampulla). This heterogeneity complicates assessment of treatment efficacy.",
"   </p>",
"   <p>",
"    The prognostic influence of these and other factors in patients with advanced biliary tract cancer can be illustrated by a Korean series of 213 patients with advanced biliary tract cancer who were either enrolled in one of two prospective phase II studies or included in a retrospective cohort study of patients receiving first-line chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/2\">",
"     2",
"    </a>",
"    ]. In multivariate analysis, metastatic disease, intrahepatic cholangiocarcinoma, the presence of liver metastases, ECOG performance status (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 1",
"    </a>",
"    ) and elevated level of serum alkaline phosphatase were significant predictors of overall survival. Using these five variables, the authors developed a prognostic index to stratify patients into low-risk, intermediate-risk, and high-risk groups with different median (11.5, 7.3, and 3.6 months, respectively) and one-year survivals (48, 26, and 4 percent, respectively).",
"   </p>",
"   <p>",
"    Although these results are not surprising, they demonstrate the variability of clinical presentation and outcomes among patients with advanced biliary tract cancer. The broad spectrum of clinical course and range of prognostic factors must be kept in mind when assessing the results of investigational studies of new treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FLUOROPYRIMIDINE-BASED REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Objective response rates with 5-FU alone and older bolus 5-FU-based combination therapies range from 0 to 34 percent, and median survival is typically short, usually less than six months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Higher response rates are reported in many series using either infusional 5-FU or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    -modulated 5-FU, although whether this translates into better survival is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/8-15\">",
"     8-15",
"    </a>",
"    ]. For unclear reasons,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    as a single agent appears relatively less active for cholangiocarcinoma than for gallbladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/16\">",
"     16",
"    </a>",
"    ], although there is some evidence of activity in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Gemcitabine plus capecitabine'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Oxaliplatin plus capecitabine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A number of combination regimens have been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Leucovorin-modulated 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    -modulated 5-FU has a favorable toxicity profile, but only modest activity. In one report of 28 patients with advanced biliary tract cancer 5-FU (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day by bolus) followed by leucovorin (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) was given on days 1 through 5, every three to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/11\">",
"     11",
"    </a>",
"    ]. There were nine objective responses (32 percent), two of which were complete and lasted for 14 and 16 months, respectively. However, median survival for the entire group was only six months.",
"   </p>",
"   <p>",
"    Regimens that combine short-term infusional FU with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (eg, the de Gramont schedule, (",
"    <a class=\"graphic graphic_table graphicRef65525 \" href=\"UTD.htm?36/17/37149\">",
"     table 2",
"    </a>",
"    )) are better tolerated than bolus regimens, but require central venous access.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     5-FU and interferon with or without cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fourteen-day cycles of 5-FU (continuous infusion of 750",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /d",
"    </span>",
"    of 5-FU on days 1 through 5) with subcutaneous interferon alpha 2b (IFN-a2b) (5",
"    <span class=\"nowrap\">",
"     MU/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 3, and 5) were given to 35 patients with biliary tract cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/10\">",
"     10",
"    </a>",
"    ]. Eleven of 32 assessable patients (34 percent) had a partial response; the median time to disease progression was 9.5 months.",
"   </p>",
"   <p>",
"    The addition of other drugs to this regimen adds toxicity but not incremental benefit. The PIAF regimen, consisting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over two hours,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over two hours, 5-FU 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    by continuous infusion daily for three days, and IFN-a2b 5",
"    <span class=\"nowrap\">",
"     MU/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 to 4, was administered to 41 patients with cancer of the gallbladder or bile duct [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/17\">",
"     17",
"    </a>",
"    ]. The overall response rate was 21 percent and higher in patients with gallbladder cancer compared to cholangiocarcinoma (35 and 10 percent, respectively). Median survival was 14 and 18 months for the cholangiocarcinoma and gallbladder cases, respectively. Toxicity was significant and included grade 3 or 4 neutropenia, thrombocytopenia, nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting, and fatigue in 41, 20, 34, and 20 percent of treated patients, respectively.",
"   </p>",
"   <p>",
"    Infusional 5-FU has also been combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/8,14,18\">",
"     8,14,18",
"    </a>",
"    ]. In one report of 25 patients with advanced biliary cancer given 5-FU (1",
"    <span class=\"nowrap\">",
"     gm/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    by continuous infusion daily for five days) and cisplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 2), there were six partial remissions (24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/8\">",
"     8",
"    </a>",
"    ]. One was a long-term survivor after receiving additional local therapy. A second trial that administered cisplatin biweekly to 29 patients reported a 34 percent overall response rate and a 6.5-month time to disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     ECF regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECF regimen (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and infusional 5-FU) is frequently used for treatment of advanced esophagogastric gastric cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44202?source=see_link&amp;anchor=H10#H10\">",
"     \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\", section on 'Combination chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Efficacy for the ECF regimen in biliary tract cancer was suggested in a trial in which 32 patients with advanced biliary or hepatocellular cancer (n = 7) received 5-FU (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day by continuous intravenous infusion throughout the treatment),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1, every 21 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/14\">",
"     14",
"    </a>",
"    ]. The objective response rate was 40 percent, and the median duration of response was 10 months.",
"   </p>",
"   <p>",
"    A somewhat lower response rate with this regimen was noted in a subsequent phase III trial that showed similar therapeutic efficacy for ECF as compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    -modulated 5-FU plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (objective response rate 19 versus 15 percent, median overall survival 9 versus 12 months, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/19\">",
"     19",
"    </a>",
"    ]. ECF was associated with significantly less acute toxicity.",
"   </p>",
"   <p>",
"    Others have explored substituting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    for infusional 5-FU in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and documented an objective response rate of 40 percent and median survival of eight months with this regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/20\">",
"     20",
"    </a>",
"    ]. However, the incidence of grade 3 or 4 neutropenia and mucositis was 26 and 19 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Capecitabine plus mitomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Promising results were reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    plus the orally active fluoropyrimidine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    in a trial of 51 patients who were randomly assigned to mitomycin C in combination with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    or capecitabine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/21\">",
"     21",
"    </a>",
"    ]. Although none of the differences were statistically significant, the group receiving mitomycin plus capecitabine had a higher response rate (31 versus 20 percent) and longer median progression-free (5.3 versus 4.2 months), as well as overall survival (9.3 versus 6.7 months).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GEMCITABINE-BASED REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, objective response rates with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone range from 7 to 27 percent, but median survival is only rarely longer than eight months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Although randomized trials have not been carried out, the combination of",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"    </span>",
"    and gemcitabine does not appear substantially more active than gemcitabine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. However, a randomized trial (the ABC trial) notes significantly better results when gemcitabine is combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    as compared to gemcitabine alone (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gemcitabine plus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is active and has been well tolerated in most [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/23,28-30\">",
"     23,28-30",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/31\">",
"     31",
"    </a>",
"    ] studies.",
"   </p>",
"   <p>",
"    The superiority of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    over gemcitabine alone was shown in the multicenter ABC-02 trial, in which 410 patients with locally advanced (25 percent) or metastatic bile duct (n = 242), gallbladder (n = 148) or ampullary (n = 20) cancer were randomly assigned to six courses of cisplatin (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    followed by gemcitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    on days 1 and 8, every 21 days, or gemcitabine alone (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1, 8, 15, every 28 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At a median follow-up of 8.2 months, median overall survival was significantly greater with combination therapy (11.7 versus 8.1 months), as was median PFS (8 versus 5 months). Toxicity was roughly comparable in both groups with the exception of significantly higher rates of grade 3 or 4 neutropenia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (25 versus 17 percent), and of grade 3 or 4 abnormal liver function with gemcitabine alone (27 versus 17 percent).",
"   </p>",
"   <p>",
"    The authors concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    should be considered the reference regimen for advanced biliary cancer. However,",
"    <span class=\"nowrap\">",
"     gemcitabine/cisplatin",
"    </span>",
"    combination has not been directly compared to other gemcitabine combinations (eg, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ) in phase III trials. A pooled analysis of 104 trials of a variety of chemotherapy regimens in advanced biliary cancer (all but three uncontrolled, only one a phase III randomized trial, not including the ABC trial discussed above) concluded that the",
"    <span class=\"nowrap\">",
"     gemcitabine/cisplatin",
"    </span>",
"    combination offered the highest rates of objective response and of tumor control (objective response plus stable disease) compared to either gemcitabine-free or cisplatin-free regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/33\">",
"     33",
"    </a>",
"    ]. However, this did not translate into significant benefit in terms of either time to tumor progression or median overall survival. Thus, in our view,",
"    <span class=\"nowrap\">",
"     gemcitabine/cisplatin",
"    </span>",
"    should be considered a standard option for advanced biliary cancer, but not the definitive reference standard.",
"   </p>",
"   <p>",
"    Efficacy and tolerability of a four-drug combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (the PEFG regimen, (",
"    <a class=\"graphic graphic_table graphicRef76548 \" href=\"UTD.htm?10/0/10251\">",
"     table 3",
"    </a>",
"    )) was suggested in an uncontrolled trial of 37 patients with advanced biliary tract adenocarcinoma (18 with cancer of the intrahepatic or extrahepatic bile ducts) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/34\">",
"     34",
"    </a>",
"    ]. A partial response was seen in 16 patients (43 percent), and the median overall survival was 12.1 months. Treatment was well tolerated, with grade 3 or 4 neutropenia, thrombocytopenia, and",
"    <span class=\"nowrap\">",
"     nausea/vomiting",
"    </span>",
"    in 18, 9, and 5 percent of cycles, respectively.",
"   </p>",
"   <p>",
"    Randomized trials are needed before it can be concluded that this regimen is more effective or safer than",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"      gemcitabine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"    </span>",
"    alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Gemcitabine plus capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    is also active for advanced biliary tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 75 patients (45 cholangiocarcinoma, three ampulla of Vater, and the rest gallbladder),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 8) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (650",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily for 14 days of every 21-day cycle) was well tolerated [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/35\">",
"       35",
"      </a>",
"      ]. There were 22 objective responses (three complete), which were seen in both tumor types (objective response rate 31 percent); an additional 42 percent had stable disease. The median progression-free and overall survival rates were 6.2 and 12.7 months, respectively.",
"     </li>",
"     <li>",
"      Both objective (tumor response, survival duration) and patient-reported outcomes were studied in another trial using a slightly different regimen (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      650",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily on days 1 to 14 plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 8, every three weeks) in 44 symptomatic patients with advanced biliary malignancy (36 biliary, eight gallbladder) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/38\">",
"       38",
"      </a>",
"      ]. Patients had to have an impaired Karnofsky performance status (60 to 80, (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 4",
"      </a>",
"      )), average analgesic consumption &ge;10 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      equivalents per day, or an average pain intensity score of &ge;20 mm out of 100 mm to be enrolled.",
"      <br/>",
"      <br/>",
"      Eleven patients had an objective response (one complete, objective response rate 25 percent) and the median time to progression and overall survival were 7.2 and 13.2 months, respectively. The most common grade 3 or 4 toxicities were fatigue and leukopenia in 11 percent of patients each and anorexia in 7 percent. After three cycles, 36 percent of patients had improvement in either performance status, pain measures, or both in addition to a &ge;7 percent increase in weight (termed a \"clinical benefit responder\"). An additional 34 percent had no worsening of performance status, pain measures, or further weight loss (termed a \"stable clinical benefit responder\"). Improved quality of life was observed in patients who met criteria for clinical benefit or stable clinical benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Randomized trials will be needed to determine if this is a more active regimen than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gemcitabine plus irinotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     Irinotecan",
"    </a>",
"    alone has modest activity in advanced biliary cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/39\">",
"     39",
"    </a>",
"    ], and at least one early report suggests benefit for the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 and 8) and irinotecan (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 and 8) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/40\">",
"     40",
"    </a>",
"    ]. Of sixteen enrolled patients (six cholangiocarcinoma, 10 gallbladder), there were two objective responses, and six additional patients had stable disease for periods ranging from 4 to 11.5 months. Although 50 percent of patients developed grade 3 to 4 myelosuppression and 28 percent grade 3 to 4 thrombocytopenia, they were transient, and there were no episodes of febrile neutropenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OXALIPLATIN COMBINATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combinations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    show promise for the treatment of advanced cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Oxaliplatin plus capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one series, 56 evaluable patients with biliary tract tumors (20 gallbladder, 36 cholangiocarcinoma) received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily on days 1 to 14) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over one hour on day 1) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/41\">",
"     41",
"    </a>",
"    ]. In a preliminary report, there were two complete and seven partial responses (overall 16 percent response rate), and a substantial number of patients had prolonged periods of stable disease. Survival was not reported.",
"   </p>",
"   <p>",
"    More favorable results (at least for extrahepatic cholangiocarcinomas) were noted in a phase II trial of 65 patients with advanced biliary cancer (38 with intrahepatic or extrahepatic cholangiocarcinoma) treated with the same regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/44\">",
"     44",
"    </a>",
"    ]. Among the patients with extrahepatic bile duct cholangiocarcinomas, there were two complete and eight partial responses. There were no partial or complete responses among patients with intrahepatic mass-forming cholangiocarcinomas. Treatment was well tolerated with only mild hematologic toxicity, grade 3 or 4 peripheral neuropathy in 11 patients of the entire cohort, and two hypersensitivity reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Oxaliplatin plus gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Others report benefit and good tolerability with GEMOX (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ) with or without 5-FU [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/42,45-48\">",
"     42,45-48",
"    </a>",
"    ]. In a phase II study of GEMOX, the response rate was 36 percent, and median overall survival duration of 15.4 months with every other week gemcitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    as a 10",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per minute infusion on day 1) and oxaliplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 2) in a select group of 33 previously untreated patients with advanced biliary cancer, a good performance status, and a serum bilirubin level &lt;2.5 times the upper limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/42\">",
"     42",
"    </a>",
"    ]. Results were less favorable in 23 other patients with poorer performance status, receiving second- or third-line therapy, or with a higher bilirubin level (response rate 22 percent, median survival 7.6 months).",
"   </p>",
"   <p>",
"    Whether these results are better than can be achieved by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    will require a randomized trial. The combination of GEMOX plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is discussed below. (See",
"    <a class=\"local\" href=\"#H5863726\">",
"     'GEMOX plus bevacizumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DOCETAXEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data as to the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    in patients with advanced cholangiocarcinoma. Modest antitumor efficacy of docetaxel monotherapy (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every 21 days) was shown in a study of 25 patients with unresectable or metastatic biliary tract carcinoma, in which there were two complete and three partial responses (overall response rate 20 percent), and grade 3 or 4 neutropenia complicated therapy in 56 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/49\">",
"     49",
"    </a>",
"    ]. Median survival was eight months.",
"   </p>",
"   <p>",
"    On the other hand, the same regimen was ineffective in a second phase II trial of 17 patients with unresectable cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/50\">",
"     50",
"    </a>",
"    ]. There is also minimal activity for the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3168565\">",
"    <span class=\"h1\">",
"     MOLECULARLY TARGETED THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Erlotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Favorable results have also been seen with blockade of the epidermal growth factor receptor using the oral tyrosine kinase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    . In one study, 42 patients with advanced biliary cancer (not stratified according to primary site), 57 percent of whom had received prior chemotherapy, received erlotinib (150 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/52\">",
"     52",
"    </a>",
"    ]. There were three partial responses (two with documented expression of EGFR) and seven additional patients remained progression-free at six months. Further experience with this drug is needed, particularly combined with cytotoxic chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3168691\">",
"    <span class=\"h2\">",
"     Erlotinib plus bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular endothelial growth factor (VEGF) is overexpressed in biliary tract cancers and has been proposed as a therapeutic target [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/53\">",
"     53",
"    </a>",
"    ]. The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , a monoclonal antibody targeting VEGF, in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    was addressed in a multinational phase II study [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/54\">",
"     54",
"    </a>",
"    ]. Fifty-three patients with advanced cholangiocarcinoma (n = 43) or gallbladder cancer (n = 10) received bevacizumab (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every two weeks) plus erlotinib (150 mg once daily). Nine patients achieved a PR, which was sustained beyond four weeks in six (12 percent), with a median response duration of 8.4 months. Stable disease was documented in 51 percent. In the entire group, the median time to disease progression was 4.4 months, and median overall survival 9.9 months. Four patients (8 percent) developed grade 4 toxicity (cerebral ischemia or thrombosis), and the most frequent grade 3 toxicity was skin rash (three patients), although in all, 40 patients developed a rash of any grade during therapy.",
"   </p>",
"   <p>",
"    Whether results from this biologic-only combination are better than can be achieved with conventional cytotoxic therapy will require a randomized trial. Although associated with significant cost (nearly $10,000 per month), this regimen could be considered as a salvage regimen after progression on standard cytotoxic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5863726\">",
"    <span class=\"h2\">",
"     GEMOX plus bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficacy for the combination of GEMOX plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    was suggested in a phase II trial in which 35 patients (all but three previously untreated) with advanced biliary tract cancer (25 cholangiocarcinoma, 10 gallbladder cancer) received bevacizumab (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on days 1 and 15) followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    at 10",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per minute) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    with cycles repeated every 28 days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/55\">",
"     55",
"    </a>",
"    ]. Fourteen patients had a confirmed partial response (41 percent); among the 22 patients with cholangiocarcinoma who were eligible for analysis, the median PFS and overall survival durations were 7.6 and 14.2 months, respectively. Bevacizumab-related toxicities included grade 3 or 4 hypertension in five, proteinuria in one, thrombosis in two, and cardiac ischemia in one. Whether these results are better than can be achieved with GEMOX alone will require a randomized trial. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Oxaliplatin plus gemcitabine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29185915\">",
"    <span class=\"h2\">",
"     GEMOX plus cetuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficacy for combined therapy with GEMOX plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , a monoclonal antibody targeting the epidermal growth factor receptor, was reported in a phase II study of 30 patients with previously untreated locally advanced or unresectable biliary tract cancer (27 cholangiocarcinoma, three gallbladder) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/56\">",
"     56",
"    </a>",
"    ]. Nineteen patients had objective responses (63 percent), of which three were complete. Nine patients with locally advanced previously unresectable disease had sufficient tumor shrinkage to permit a later potentially curative resection, but long-term outcomes were not reported. Further study of this combination is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4894063\">",
"    <span class=\"h2\">",
"     GEMOX plus erlotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    to GEMOX was directly studied in a randomized trial in which 268 patients with cholangiocarcinoma, gallbladder cancer, or ampullary cancer were randomly assigned to GEMOX with or without erlotinib (100 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/57\">",
"     57",
"    </a>",
"    ]. The objective tumor response rate was higher with combined therapy (30 versus 16 percent), but progression-free survival, the primary endpoint, was not significantly better (median 5.8 versus 4.2 months). In an unplanned analysis restricted to the subgroup with cholangiocarcinoma (n = 180), the difference in median PFS favoring erlotinib was statistically significant (5.9 versus 3 months). Grade 3 or 4 toxicities were uncommon in both groups, and none were significantly more frequent with combined therapy. However, more patients in the erlotinib group required dose reductions because of treatment-related toxicities (64 versus 43 percent).",
"   </p>",
"   <p>",
"    While these results are suggestive, additional data are needed to address the utility of this combination for first-line treatment of patients with cholangiocarcinoma, and particularly whether it represents an advance over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus weekly low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . The trial was conducted exclusively in South Korea, and whether the results can be extrapolated to other ethnic groups is unclear. Furthermore, additional studies are required to determine if responses correlate with EGFR mutation as might be expected from the larger experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    in non-small cell lung cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link&amp;anchor=H1506273#H1506273\">",
"     \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\", section on 'Erlotinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of systemic chemotherapy is evolving in patients with advanced cholangiocarcinoma. No single chemotherapy agent or combination regimen consistently leads to objective tumor shrinkage, forestalls recurrent obstruction following palliative intervention, or extends survival beyond 8 to 15 months. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    has been shown to be superior to gemcitabine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10761/abstract/23\">",
"     23",
"    </a>",
"    ], this regimen has not been compared head to head with other gemcitabine-based combinations. We prefer that patients enroll in clinical trials, whenever possible.",
"   </p>",
"   <p>",
"    Nevertheless, if a patient is not a candidate for a clinical trial or if one is not available, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    as a potentially better-tolerated agent) for a first-line regimen for patients with a good performance status (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Gemcitabine plus cisplatin'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Gemcitabine plus irinotecan'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Oxaliplatin plus gemcitabine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    -modulated 5-FU (",
"    <a class=\"graphic graphic_table graphicRef65525 \" href=\"UTD.htm?36/17/37149\">",
"     table 2",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    monotherapy, or single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef60330 \" href=\"UTD.htm?35/56/36749\">",
"     table 5",
"    </a>",
"    ) are reasonable options for patients with a borderline performance status. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Leucovorin-modulated 5-FU'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Gemcitabine-based regimens'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34561?source=see_link\">",
"     \"Treatment protocols for hepatobiliary cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who retain an adequate performance status, active regimens that could be considered for second-line therapy include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H3168565\">",
"     'Molecularly targeted therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Gemcitabine plus capecitabine'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/1\">",
"      Glimelius B, Hoffman K, Sj&ouml;d&eacute;n PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/2\">",
"      Park I, Lee JL, Ryu MH, et al. Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer 2009; 115:4148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/3\">",
"      Kajanti M, Pyrh&ouml;nen S. Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol 1994; 17:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/4\">",
"      Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984; 2:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/5\">",
"      Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984; 54:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/6\">",
"      Takada T, Kato H, Matsushiro T, et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994; 51:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/7\">",
"      Gebbia V, Majello E, Testa A, et al. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Cancer 1996; 78:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/8\">",
"      Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 1998; 9:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/9\">",
"      Sanz-Altamira PM, Ferrante K, Jenkins RL, et al. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 1998; 82:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/10\">",
"      Patt YZ, Jones DV Jr, Hoque A, et al. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 1996; 14:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/11\">",
"      Choi CW, Choi IK, Seo JH, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 2000; 23:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/12\">",
"      Penz M, Kornek GV, Raderer M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001; 12:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/13\">",
"      Chen JS, Jan YY, Lin YC, et al. Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. Anticancer Drugs 1998; 9:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/14\">",
"      Ellis PA, Norman A, Hill A, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 1995; 31A:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/15\">",
"      Malik IA, Aziz Z. Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder. Am J Clin Oncol 2003; 26:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/16\">",
"      Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004; 101:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/17\">",
"      Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 2001; 7:3375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/18\">",
"      Ta&iuml;eb J, Mitry E, Boige V, et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 2002; 13:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/19\">",
"      Rao S, Cunningham D, Hawkins RE, et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005; 92:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/20\">",
"      Park SH, Park YH, Lee JN, et al. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer 2006; 106:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/21\">",
"      Kornek GV, Schuell B, Laengle F, et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 2004; 15:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/22\">",
"      Park JS, Oh SY, Kim SH, et al. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol 2005; 35:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/23\">",
"      Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer 2009; 101:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/24\">",
"      Suzuki E, Furuse J, Ikeda M, et al. Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases. Oncology 2010; 79:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/25\">",
"      Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 2001; 19:4089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/26\">",
"      Jacobson SD, Alberts SR, Mahoney MR, et al. Phase II trial of gemcitabine, 5-fluorouracil, and leucovorin in patients with unresectable or metastatic biliary and gallbladder carcinoma (abstract). Proc Am Soc Clin Oncol 2003; 22:275a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/27\">",
"      Alberts SR, Al-Khatib H, Mahoney MR, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005; 103:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/28\">",
"      Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005; 16:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/29\">",
"      Giuliani F, Gebbia V, Maiello E, et al. Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol 2006; 17 Suppl 7:vii73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/30\">",
"      Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/31\">",
"      Meyerhardt JA, Zhu AX, Stuart K, et al. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci 2008; 53:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/32\">",
"      Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/33\">",
"      Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/34\">",
"      Cereda S, Passoni P, Reni M, et al. The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer 2010; 116:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/35\">",
"      Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/36\">",
"      Cho JY, Paik YH, Chang YS, et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 2005; 104:2753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/37\">",
"      Riechelmann RP, Townsley CA, Chin SN, et al. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007; 110:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/38\">",
"      Koeberle D, Saletti P, Borner M, et al. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2008; 26:3702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/39\">",
"      Sanz-Altamira PM, O'Reilly E, Stuart KE, et al. A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol 2001; 12:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/40\">",
"      Bhargava P, Jani CR, Savarese DM, et al. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Oncology (Williston Park) 2003; 17:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/41\">",
"      Nehls O, Oettle H, Hartmann JT, et al. A multicentre phase II study of capecitabine plus oxaliplatin in advanced biliary system adenocarcinomas (abstract). Proc Am Soc Clin Oncol 2004; 23:336s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/42\">",
"      Andr&eacute; T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/43\">",
"      Verderame F, Russo A, Di Leo R, et al. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Ann Oncol 2006; 17 Suppl 7:vii68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/44\">",
"      Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008; 98:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/45\">",
"      Harder J, Riecken B, Kummer O, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006; 95:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/46\">",
"      Manzione L, Romano R, Germano D. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience. Oncology 2007; 73:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/47\">",
"      Andr&eacute; T, Reyes-Vidal JM, Fartoux L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008; 99:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/48\">",
"      Wagner AD, Buechner-Steudel P, Moehler M, et al. Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. Br J Cancer 2009; 101:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/49\">",
"      Papakostas P, Kouroussis C, Androulakis N, et al. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. Eur J Cancer 2001; 37:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/50\">",
"      Pazdur R, Royce ME, Rodriguez GI, et al. Phase II trial of docetaxel for cholangiocarcinoma. Am J Clin Oncol 1999; 22:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/51\">",
"      Kuhn R, Hribaschek A, Eichelmann K, et al. Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs 2002; 20:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/52\">",
"      Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006; 24:3069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/53\">",
"      Park BK, Paik YH, Park JY, et al. The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma. Am J Clin Oncol 2006; 29:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/54\">",
"      Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 2010; 28:3491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/55\">",
"      Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010; 11:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/56\">",
"      Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 2010; 11:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10761/abstract/57\">",
"      Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012; 13:181.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2524 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-115.25.216.6-EAABC7EE5F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10761=[""].join("\n");
var outline_f10_32_10761=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES OF CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FLUOROPYRIMIDINE-BASED REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Leucovorin-modulated 5-FU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      5-FU and interferon with or without cisplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ECF regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Capecitabine plus mitomycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GEMCITABINE-BASED REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gemcitabine plus cisplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Gemcitabine plus capecitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gemcitabine plus irinotecan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OXALIPLATIN COMBINATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Oxaliplatin plus capecitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Oxaliplatin plus gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DOCETAXEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3168565\">",
"      MOLECULARLY TARGETED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Erlotinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3168691\">",
"      Erlotinib plus bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5863726\">",
"      GEMOX plus bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29185915\">",
"      GEMOX plus cetuximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4894063\">",
"      GEMOX plus erlotinib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2524\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2524|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/17/37149\" title=\"table 2\">",
"      Modified de Gramont schedule for gastrointestinal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/0/10251\" title=\"table 3\">",
"      PEFG regimen pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 4\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/56/36749\" title=\"table 5\">",
"      Gemcitabine for metastatic pancreatic and biliary tract cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=related_link\">",
"      Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3674?source=related_link\">",
"      Ampullary carcinoma: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44202?source=related_link\">",
"      Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=related_link\">",
"      Clinical manifestations and diagnosis of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43881?source=related_link\">",
"      Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15082?source=related_link\">",
"      Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/33/25114?source=related_link\">",
"      Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34728?source=related_link\">",
"      Treatment options for locally advanced cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34561?source=related_link\">",
"      Treatment protocols for hepatobiliary cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_32_10762="Retinopathy of prematurity";
var content_f10_32_10762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Retinopathy of prematurity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/32/10762/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10762/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/32/10762/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10762/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10762/contributors\">",
"     Richard A Saunders, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/32/10762/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/32/10762/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/32/10762/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinopathy of prematurity (ROP), formerly known as retrolental fibroplasia because of its end-stage appearance, is a developmental vascular proliferative disorder that occurs in the retina of preterm infants with incomplete retinal vascularization. Next to cortical blindness, ROP is the most common cause of childhood blindness in the United States. Other ophthalmologic disorders that occur frequently in preterm infants include amblyopia, strabismus, and refractive errors.",
"   </p>",
"   <p>",
"    An overview of ROP will be provided below. Other common eye problems in premature infants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=see_link\">",
"     \"Refractive errors in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link\">",
"     \"Overview of amblyopia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link\">",
"     \"Evaluation and management of strabismus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OCULAR CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The size and characteristics of the eye differ in premature and term infants:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The globe diameter is approximately 10 to 14 mm at 28 weeks&rsquo; gestation, compared with 16 to 17 mm at term.",
"     </li>",
"     <li>",
"      The cornea and vitreous may be hazy in premature infants and impede visualization of the fundus. Small peripheral lens vacuoles are common. In addition, an incompletely involuted hyaloid artery may appear as a white or red strand in the vitreous.",
"     </li>",
"     <li>",
"      The blood vessels in the anterior vascular capsule of the lens regress in a consistent pattern and correlate well with gestational age between 27 and 34 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pupillary size in premature infants is approximately 3 to 4 mm, slightly smaller than at term. Constriction of the pupils in response to light starts at approximately 30 to 32 weeks&rsquo; gestation and is consistently present after 35 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tear production is reduced in premature infants and may result in drying of the corneas during an eye examination, increased absorption of topically applied medications, or masking the diagnosis of a congenital lacrimal duct obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Normal vascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sequence of vascularization of the eye is important in understanding the pathogenesis of retinopathy of prematurity (ROP). No blood vessels are present in the retina before approximately 16 weeks&rsquo; gestation. From approximately the sixth week, the anterior segment of the eye receives its vascular supply from the hyaloid artery. This artery originates from the optic nerve, passes through the vitreous, and supplies vessels to both surfaces of the lens and iris. These vessels usually are resorbed by 34 weeks of gestation.",
"   </p>",
"   <p>",
"    Retinal vascularization begins at 15 to 18 weeks&rsquo; gestation. Retinal blood vessels extend out from the optic disc (where the optic nerve enters the eye) and grow peripherally. Vascularization in the nasal retina is complete at approximately 36 weeks. Vascular development usually is complete in the temporal retina by 40 weeks, although maturation may be delayed until 48 to 52 weeks&rsquo; postmenstrual age in premature infants (",
"    <a class=\"graphic graphic_figure graphicRef81538 \" href=\"UTD.htm?19/27/19903\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vascularization in ROP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of ROP is not well understood. The mechanism is thought to involve two stages. An initial injury caused by factors such as hypotension, hypoxia, or hyperoxia, with free radical formation, injures newly developing blood vessels and disrupts normal angiogenesis. Following this disruption, vessels either resume normal growth or new vessels grow abnormally out from the retina into the vitreous. Increased permeability of these abnormal new vessels (neovascularization) can result in retinal edema and hemorrhage. Abnormal fibrovascular tissue may develop along with the neovascularization and later contract, producing traction on the retina. In some severe cases, this results in retinal distortion or retinal detachment. However, in most instances, the abnormal vascular tissue regresses with little residual effect.",
"   </p>",
"   <p>",
"    Regulation of the expression of vascular endothelial growth factor (VEGF) and other cytokines may contribute to both normal retinal vessel growth and abnormal vascular disruption and subsequent neovascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]. The mechanisms that determine whether initial disruption of normal angiogenesis in ROP will be followed by resumption of normal vascular development or progression of pathologic neovascularization are unknown.",
"   </p>",
"   <p>",
"    Insulin-like growth factor-1 (IGF-1) supports normal retinal vascular growth and interacts with VEGF [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. The possible role of IGF-1 in ROP has been evaluated in several series of preterm infants who had serial blood samples and retinal examinations. In each of these series, decreased serum concentrations of IGF-1 were associated with the development of ROP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/14-18\">",
"     14-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With low IGF-1, vessels cease to grow, the maturing avascular retina becomes hypoxic, and VEGF accumulates. Later, as IGF-1 levels rise during maturation and reach a critical level, neovascularization ensues.",
"   </p>",
"   <p>",
"    Activation of a specific VEGF receptor may protect developing retinal vessels and prevent retinal ischemia induced by oxygen. This was investigated in a study in newborn mice, in which activation of the VEGF receptor VEGFR-1 by placental growth factor-1 (PlGF-1) decreased the obliteration of retinal vessels by hyperoxia (22 versus 5 percent) and did not induce neovascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/19\">",
"     19",
"    </a>",
"    ]. Stimulation of another VEGF receptor, VGEFR-2, had no effect on blood vessel survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Photoreceptor development",
"    </span>",
"    &nbsp;&mdash;&nbsp;ROP appears to affect photoreceptor development. An observational study in which retinal sensitivity and retinal responsivity were assessed by electroretinography between 30 and 72 weeks&rsquo; PMA suggests that photoreceptor development is altered in prematurity (with or without ROP); that conditions that affect the photoreceptor cells (eg, ROP, ROP treatment) appear to reduce sensitivity; and that retinal neuronal behavior may be influenced by extrauterine experience [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinopathy of prematurity (ROP) affects a substantial number of premature infants worldwide. Both the incidence and severity increase with decreasing gestational age (GA) and birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/22-26\">",
"     22-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 951 preterm infants born (&lt;37 weeks&rsquo; GA) at a single center between 1989 and 1997, ROP developed in 21 percent of patients and severe ROP in 5 percent (stage 3 or greater) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/22\">",
"     22",
"    </a>",
"    ]. No infant born at more than 32 weeks&rsquo; GA developed the disorder, and no infant born later than 28 weeks&rsquo; GA needed retinal surgery. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Stage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a multicenter study conducted in the United States between October 2000 and October 2002, the incidence of ROP in preterm infants (birth weights &lt;1251 g) was 68 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/27\">",
"     27",
"    </a>",
"    ]. The overall incidence of severe ROP was 36 percent. The incidence of ROP was 8 percent, 19 percent, and 43 percent among infants born at &ge;32 weeks&rsquo;, &gt;27 to 31 weeks&rsquo;, and &le;27 weeks&rsquo; gestation, respectively.",
"   </p>",
"   <p>",
"    The increased incidence of severe ROP with decreasing GA also was demonstrated in a population-based cohort study from New Zealand and Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/24\">",
"     24",
"    </a>",
"    ]. The overall incidence of severe ROP among infants born at less than 32 weeks&rsquo; GA was 10 percent. Severe ROP increased from 3 to 34 percent as gestational age decreased from 27 to 24 weeks, respectively.",
"   </p>",
"   <p>",
"    These studies, which were conducted in developed countries, suggest that infants born at &ge;32 weeks are not at risk for developing ROP. In addition, most infants born at &gt;28 weeks who develop ROP have mild disease that does not require treatment.",
"   </p>",
"   <p>",
"    In developing countries, the infants who develop severe ROP are larger and are of a greater estimated GA than those in developed countries. A survey of ophthalmologists from low, moderate, and highly developed countries found that the mean birth weight of infants with severe ROP was greater in infants in developing than in developed countries (900 versus 750 gm) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/28\">",
"     28",
"    </a>",
"    ]. Similarly, the mean GA of infants with severe ROP was greater in developing than in developed countries (26 to 33.5 versus 25 weeks).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important risk factor for developing ROP is prematurity. However, more than 50 separate risk factors have been identified. In multivariate analysis, low birth weight, low gestational age, assisted ventilation for longer than one week, surfactant therapy, high blood transfusion volume, cumulative illness severity, hyperglycemia, and insulin therapy, have been independently associated with higher rates of ROP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/29-33\">",
"     29-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other possible risk factors include sepsis, fluctuations in blood gas measurements, intraventricular hemorrhage, bronchopulmonary dysplasia, systemic fungal infection, and early administration of erythropoietin for the treatment of anemia of prematurity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/29,30,34\">",
"     29,30,34",
"    </a>",
"    ]. The risk of developing ROP also appears to be related to longitudinal weight gain and serum concentrations of IGF-1 and IGFBP-3 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/16,35,36\">",
"     16,35,36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Vascularization in ROP'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=see_link&amp;anchor=H15#H15\">",
"     \"Anemia of prematurity\", section on 'Early EPO use'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated arterial oxygen tension is also thought to contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. However, ROP is not the only consideration in determination of target oxygen concentration in preterm infants. Decreased target oxygenation saturation has been associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=see_link&amp;anchor=H20#H20\">",
"     \"Oxygen monitoring and therapy in the newborn\", section on 'High versus low SpO2 target'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infection may worsen the course of ROP. In one study of affected infants, those with candidemia were more likely to reach threshold ROP and require surgical intervention (OR 7.4, 95% CI 1.7-32.1) compared with those without candidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/40\">",
"     40",
"    </a>",
"    ]. Infection was also associated with poor outcome following laser photocoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Classification for Retinopathy of Prematurity (ICROP) provides a uniform approach to documenting the extent and severity of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. This system facilitates communication among care providers and promotes collaborative clinical investigation. Four features are evaluated: zone, stage, extent, and presence or absence of plus disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Features",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Zone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of the retinopathy within the retina is defined by dividing the eye into three zones, centered on the optic nerve (",
"    <a class=\"graphic graphic_figure graphicRef81495 \" href=\"UTD.htm?8/3/8254\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Zone I, the central zone at the posterior pole of the eye, has a radius of twice the distance from the optic disc to the macula and subtending an arc of 60 degrees centered on the disc.",
"     </li>",
"     <li>",
"      Zone II forms a circle outside zone I with a radius from the optic nerve to the nasal ora serrata.",
"     </li>",
"     <li>",
"      Zone III is the remaining temporal crescent of retina.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The five stages indicate the increasing severity of disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 1 consists of a flat white line that demarcates the vascular and avascular retina (",
"      <a class=\"graphic graphic_picture graphicRef57409 \" href=\"UTD.htm?42/62/44015\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In stage 2, a ridge of fibrous tissue protrudes into the vitreous in the region between the vascular and avascular retina (",
"      <a class=\"graphic graphic_picture graphicRef67145 \" href=\"UTD.htm?6/27/6590\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In stage 3, new blood vessels and fibrous tissue grow along the ridge and often extend into the vitreous (",
"      <a class=\"graphic graphic_picture graphicRef79144 \" href=\"UTD.htm?16/6/16495\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Stage 4 signifies a partial retinal detachment. It is further subdivided into stages 4A and 4B, depending upon whether the detachment excludes or includes the macula, respectively (",
"      <a class=\"graphic graphic_figure graphicRef59973 \" href=\"UTD.htm?11/31/11762\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Stage 5 denotes a total retinal detachment (",
"      <a class=\"graphic graphic_picture graphicRef67635 \" href=\"UTD.htm?13/43/14000\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a large natural history study, stages 1, 2, and 3 occurred at a median postmenstrual age of 34.3, 35.4, and 36.6 weeks, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Extent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of disease is described by dividing the retinal surface into 30&ordm; sectors, similar to the hours of a clock. As many as 12 clock hours can be affected, and the stage of retinopathy can vary among sectors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Plus disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plus disease refers to dilation and tortuosity of the retinal arterioles and venules in the posterior pole of the retina (",
"    <a class=\"graphic graphic_picture graphicRef69596 \" href=\"UTD.htm?6/32/6671\">",
"     picture 5",
"    </a>",
"    ) as defined by a standard photograph [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/42\">",
"     42",
"    </a>",
"    ]. This indicates severe retinopathy of prematurity (ROP), perhaps caused by excessive shunting of blood through the neovascular tissue at the ridge, but more likely represents a direct effect of VEGF acting on the retinal blood vessels. The development of plus disease is an ominous clinical sign that often is followed by rapid progression to retinal detachment.",
"   </p>",
"   <p>",
"    Vitreous haze, engorgement of the iris vessels, and poor dilation of the pupil sometimes accompany plus disease, and are additional indicators of poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A rare, but more serious variant of ROP is termed &ldquo;aggressive posterior ROP&rdquo;. Aggressive posterior ROP is characterized by severe plus disease, more subtle retinal findings, posterior location, and rapid progression. Its prognosis is believed to be worse than ROP with more conventional presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pre-plus disease is defined as dilation and tortuosity of the posterior pole arterioles and venules that are insufficient for the diagnosis of plus disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/42\">",
"     42",
"    </a>",
"    ]. It is the precursor to plus disease and, in one study, predicted progression to severe ROP that required treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Threshold ROP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Threshold ROP is defined as five contiguous clock hours or eight total clock hours of stage 3 and plus disease in zone I or II.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prethreshold ROP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prethreshold ROP is defined as one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ROP at any stage less than threshold in zone I",
"     </li>",
"     <li>",
"      Stage 2 and plus disease in zone II",
"     </li>",
"     <li>",
"      Stage 3 without plus disease in zone II",
"     </li>",
"     <li>",
"      Stage 3 with plus disease in zone II but with fewer clock hours of stage 3 than required to meet threshold",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High-risk prethreshold ROP includes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Any stage ROP with plus disease in zone I",
"     </li>",
"     <li>",
"      Stage 3 ROP without plus disease in zone I",
"     </li>",
"     <li>",
"      Stage 2 or 3 ROP with plus disease in zone II",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of retinopathy of prematurity (ROP) is more correlated with postmenstrual age (PMA) than postnatal age. ROP typically begins about 34 weeks&rsquo; PMA, although it may be seen as early as 30 to 32 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/23\">",
"     23",
"    </a>",
"    ]. ROP advances irregularly until 40 to 45 weeks&rsquo; PMA but resolves spontaneously in the majority of infants. In a natural history study, in which two-thirds of infants with birth weight &le;1250 g developed ROP, treatment for severe disease was needed in only 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regression of ROP also depends upon PMA and the location of disease. In one report of 766 children from the natural history study, involution began at a mean PMA of 38.6 weeks, and before 44 weeks in 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/46\">",
"     46",
"    </a>",
"    ]. The outcome was favorable in 99 percent of infants when ROP resolved by moving from zone II to III. Partial or total retinal detachment was never seen when ROP was limited to zone III in serial examinations.",
"   </p>",
"   <p>",
"    Ocular outcome is poor in infants with untreated severe ROP. This was evaluated at 5.5 years&rsquo; corrected age in infants with birth weight &le;1250 g who were enrolled in the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/47\">",
"     47",
"    </a>",
"    ]. Among untreated eyes, poor structural outcomes (eg, retinal folding, severe retinal detachment) occurred in 3.1 percent of eyes, and poor Snellen visual acuity",
"    <span class=\"nowrap\">",
"     (20/200",
"    </span>",
"    or worse) occurred in 5.1 percent of eyes. All poor structural outcomes and nearly all poor visual acuity outcomes had a history of severe ROP (zone II ROP involving &gt;6 clock hours of stage 3+ disease or zone I ROP). Poor visual acuity occurred in only 2 of 110 eyes (1.8 percent) when ROP was observed only in zone III.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The screening evaluation consists of a comprehensive eye examination performed by an ophthalmologist with expertise in neonatal disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/48\">",
"     48",
"    </a>",
"    ]. The pupil must be dilated in order to visualize the vitreous and retina. We recommend instillation in the eye of a combination eyedrop (Cyclomydril, which contains weak concentrations of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/46/41696?source=see_link\">",
"     phenylephrine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/3/31795?source=see_link\">",
"     cyclopentolate",
"    </a>",
"    ) 30 minutes before the examination. Both manipulation of the eye and the drops used to dilate the pupil can produce systemic sequelae, most notably bradycardia and cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/49\">",
"     49",
"    </a>",
"    ]. Therefore, careful monitoring of the infant throughout the examination procedure is essential. Topical anesthetic can be used if the examining clinician prefers.",
"   </p>",
"   <p>",
"    The retina is examined by looking through the pupil with an indirect ophthalmoscope and a 20 or 28 diopter condensing lens while the eyelids are retracted with a speculum. Retinopathy of prematurity (ROP) is most commonly visualized in the peripheral retina, which often is obscured by the iris. In order to completely view this area, a scleral depressor is used to indent the eye externally. ROP, if present, is described using the standardized classification. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Screening criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;We screen",
"    <strong>",
"     all",
"    </strong>",
"    infants with birth weight &le;1500 g or a gestational age (GA) of less than 30 weeks, as well as those with birth weight between 1500 g and 2000 g or a GA of more than 30 weeks whose clinical course places them at increased risk for ROP (as determined by the attending clinician) as per the 2013 Joint Statement of the American Academy of Pediatrics (AAP) Section on Ophthalmology, the American Academy of Ophthalmology (AAO), the American Association for Pediatric Ophthalmology and Strabismus (AAPOS), and the American Association of Certified Orthoptists (AACO) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/48\">",
"     48",
"    </a>",
"    ]. These screening criteria, however, are controversial. In a Canadian study, screening infants with a birth weight of 1200 g or less was the most cost-effective strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening for ROP is a labor-intensive process with a relatively low yield; less than 10 percent of infants who are screened require treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/51\">",
"     51",
"    </a>",
"    ]. Incorporation of postnatal risk factors into the screening guidelines may increase the yield of screening. Models using various combinations of gestational age, birth weight, postnatal weight gain, and serum IGF-1 levels to predict increased risk of severe ROP have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/35,36,52-55\">",
"     35,36,52-55",
"    </a>",
"    ]. In initial validation studies, the sensitivity of these models approached 100 percent, and the specificity ranged from 32 to 84 percent. However, in a subsequent retrospective validation, the sensitivity of one such model using weight and IGF-1 level in detecting severe ROP among Mexican infants born at &lt;32 weeks gestation was only 84.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/56\">",
"     56",
"    </a>",
"    ]. The use of models incorporating postnatal risk factors to screen for increased risk of severe ROP has the potential to reduce the number of infants requiring ophthalmologic examinations. However, these methods require additional validation in other populations before changes to the current screening recommendations can be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Evaluation schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;We initiate screening examinations at four to eight weeks after birth, depending upon the GA (at 30 weeks&rsquo; PMA for infants born at 22 to 26 weeks and at 4 weeks of chronologic age for children born at &ge;27 weeks) (",
"    <a class=\"graphic graphic_table graphicRef77995 \" href=\"UTD.htm?28/28/29131\">",
"     table 1",
"    </a>",
"    ). Our screening schedule conforms to evidence-based screening criteria, which were developed for infants with birth weight &le;1250 g or GA &lt;31 weeks based upon natural history data from two large randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In these studies, retinal conditions that indicated a risk of poor outcome were not observed before 31 weeks postmenstrual age (PMA) or 4 weeks postnatal age in 99 percent of infants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/59\">",
"     59",
"    </a>",
"    ]. Although treatable ROP rarely occurs before 31 weeks PMA, we initiate screening at 30 weeks PMA to account for the possibility of errors in dating and to permit flexibility in scheduling.",
"   </p>",
"   <p>",
"    Additional examinations are performed at intervals of one to three weeks until the retinal vessels have completely grown out to the ora serrata. If ROP develops, the eyes are examined more frequently, depending upon the severity of disease and rate of progression. The",
"    <span class=\"nowrap\">",
"     AAP/AAO/AAPOS/AACO",
"    </span>",
"    joint statement suggests follow-up examinations according to the following schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follow-up within one week is recommended for infants with [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/48,60\">",
"     48,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immature vascularization in zone I, without ROP",
"     </li>",
"     <li>",
"      Immature retina that extends into posterior zone II, near the boundary of zone I",
"     </li>",
"     <li>",
"      Stage 1 or 2 ROP in zone I",
"     </li>",
"     <li>",
"      Stage 3 ROP in zone II",
"     </li>",
"     <li>",
"      Suspected aggressive posterior ROP",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Follow-up within one to two weeks is recommended for infants with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immature vascularization in posterior zone II",
"     </li>",
"     <li>",
"      Stage 2 ROP in zone II",
"     </li>",
"     <li>",
"      Regressing ROP in zone I",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Follow-up within two weeks is recommended for infants with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 1 ROP in zone II",
"     </li>",
"     <li>",
"      Immature vascularization in zone II, without ROP",
"     </li>",
"     <li>",
"      Regressing ROP in zone II",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Follow-up within two to three weeks is recommended for infants with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 1 or 2 ROP in zone III",
"     </li>",
"     <li>",
"      Regressing ROP in zone III",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When an infant is discharged home before the retinal vasculature is mature, parents must understand the importance of timely follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/48,61\">",
"     48,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening examinations continue until ROP regresses and the vasculature matures or treatment is needed. Screening examinations can be discontinued when any of the following conditions occurs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of development of prethreshold (stage 3 ROP in zone II or any ROP in zone I) or worse ROP by 50 weeks&rsquo; postmenstrual age",
"     </li>",
"     <li>",
"      Progression of retinal vascularization into zone III without previous ROP in zone I or zone II",
"     </li>",
"     <li>",
"      Documented mild, regressing ROP in zone III in a low-risk infant",
"     </li>",
"     <li>",
"      Full retinal vascularization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In large randomized trials, these signs indicated that the risk of visual loss from ROP was minimal or had passed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/46,57,58\">",
"     46,57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal ablative therapy is indicated for eyes with threshold retinopathy of prematurity (ROP) and eyes with high-risk prethreshold retinopathy of prematurity (ROP) based on clinical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/48,51,62\">",
"     48,51,62",
"    </a>",
"    ]. Threshold ROP is defined as five contiguous clock hours or eight total clock hours of stage 3 and plus disease in zone I or II. High-risk prethreshold ROP includes (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Classification'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Zone I: any stage ROP with plus disease",
"     </li>",
"     <li>",
"      Zone I: stage 3 ROP without plus disease",
"     </li>",
"     <li>",
"      Zone II: stage 2 or 3 ROP with plus disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Close observation should continue for eyes that do not meet criteria for high-risk prethreshold ROP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Evaluation schedule'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The indications for retinal ablative therapy are supported by two multicenter randomized trials with long-term follow-up: the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) and the Early Treatment for Retinopathy of Prematurity (ETROP) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/45,51,57,63-68\">",
"     45,51,57,63-68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CRYO-ROP trial demonstrated the efficacy of cryotherapy compared with no treatment for infants with threshold ROP [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/57,63,64\">",
"       57,63,64",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Cryotherapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The ETROP trial included infants with bilateral \"high-risk\" prethreshold ROP (defined as &gt;15 percent risk of unfavorable outcome without treatment according to an algorithm based on data from the CRYO-ROP trial) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/45,51,65\">",
"       45,51,65",
"      </a>",
"      ]. One eye was randomly assigned to early treatment and the other eye to conventional management. Early treatment reduced unfavorable visual acuity (14.5 versus 19.5 percent) and unfavorable structural outcomes (9.1 versus 15.6 percent) at nine months&rsquo; corrected age. At age six years, early-treated eyes continued to have fewer unfavorable structural outcomes (8.9 versus 15.2 percent) and relatively preserved peripheral vision [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/66,67\">",
"       66,67",
"      </a>",
"      ]. At age six years, visual acuity outcomes were no longer statistically superior (24.6 versus 29.0 percent unfavorable, p = 0.15) in the early treatment group; however, in subgroup analysis, early treatment improved visual acuity outcome for &ldquo;higher-risk&rdquo; prethreshold eyes [",
"      <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/67,68\">",
"       67,68",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The benefit of early treatment in the ETROP trial was largely driven by improved outcomes in zone I eyes (41 percent of the cohort). This caveat may be helpful in making treatment decisions for infants with borderline treatment indications (eg, zone II eyes starting to show signs of involution).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard treatment consists of ablation of the peripheral avascular retina by cryotherapy or laser photocoagulation. Retinal ablative therapy reduces the incidence of adverse structural and functional outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Unfortunately, despite appropriate treatment, threshold ROP progresses to retinal detachment in 15 to 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/69\">",
"     69",
"    </a>",
"    ]. When treatment is indicated, it should be undertaken as soon as practicable, and almost always within 72 hours of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Indications for treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Cryotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryotherapy was the only proven treatment for ROP until the early 1990s, but it has been largely replaced by laser photocoagulation as standard therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/71\">",
"     71",
"    </a>",
"    ]. The procedure involves freezing the peripheral retina through the wall of the eye, including sclera and choroid, and is performed using local or general anesthesia.",
"   </p>",
"   <p>",
"    The safety and efficacy of cryotherapy were demonstrated in a large multicenter trial in which 291 infants with threshold ROP were randomly assigned to cryotherapy or no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/57\">",
"     57",
"    </a>",
"    ]. Significantly fewer treated eyes had an unfavorable outcome, defined as posterior retinal detachment, posterior retinal fold, or retrolental tissue that obscured visualization of the posterior pole (31 versus 51 percent), at three months. The benefit was sustained at 12 months after randomization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/63\">",
"     63",
"    </a>",
"    ]. Continued benefit of cryotherapy was demonstrated at 15-year follow-up in 254 survivors of the original cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/64\">",
"     64",
"    </a>",
"    ]. Outcome measures included evaluation of ocular structure and visual acuity. Significantly fewer treated than untreated eyes had poor ocular structure, including new retinal folds, retinal detachments, and obstruction of the view of the posterior pole (30 versus 52 percent). In addition, significantly fewer treated than untreated eyes had poor visual acuity, defined as",
"    <span class=\"nowrap\">",
"     20/200",
"    </span>",
"    or worse (45 versus 64 percent).",
"   </p>",
"   <p>",
"    Cryotherapy often causes conjunctival chemosis and can result in anterior and posterior inflammation or, in rare cases, more serious complications, such as serous retinal detachment (fluid under the retina) or macular scarring. Some infants, especially those who have bronchopulmonary dysplasia or are given general anesthesia, may develop respiratory decompensation during or after the procedure and need assisted ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Photocoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laser photocoagulation, using the diode or argon laser, has become standard treatment for ROP. The laser, mounted on an indirect ophthalmoscope, is aimed through the pupil and focused on the avascular retina using a condensing lens like the one used for retinal viewing.",
"   </p>",
"   <p>",
"    Structural and visual outcomes suggest that laser photocoagulation is at least as effective as is cryotherapy and most likely superior, although comparative data typically depend upon historical controls or smaller controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. As an example, cryotherapy and laser photocoagulation, which were performed during different time periods, were compared in a retrospective record review [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/72\">",
"     72",
"    </a>",
"    ]. ROP resolved in more eyes evaluated in the laser than in the cryotherapy group (88 versus 56 percent), and visual acuity at 12 months of age was significantly better in the laser group.",
"   </p>",
"   <p>",
"    The short-term observational data that functional and structural outcomes are better with laser than cryotherapy are supported by long-term follow-up of participants in a randomized trial comparing these treatments. In two reports, 44 eyes in 25 patients who were randomly assigned to cryotherapy or laser therapy for threshold ROP (of 118 eyes in 66 patients in the initial group [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]) were evaluated after 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Compared with cryotherapy, outcomes in the eyes treated with laser included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Better mean best-corrected visual acuity",
"      <span class=\"nowrap\">",
"       (20/66",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       20/182",
"      </span>",
"      (Snellen equivalent))",
"     </li>",
"     <li>",
"      Smaller likelihood of developing retinal dragging",
"     </li>",
"     <li>",
"      Less myopia, demonstrated by a lower mean spherical equivalent (-4.48 versus -7.65 diopters)",
"     </li>",
"     <li>",
"      Greater mean axial length (22.9 versus 21.7 mm) and anterior chamber depth (3.42 versus 2.86 mm) and decreased lens thickness (3.95 versus 4.33 mm)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laser treatment also appears to be better tolerated than is cryotherapy. Infants are less likely to have conjunctival chemosis, inflammation, pain, or apnea and bradycardia following the procedure.",
"   </p>",
"   <p>",
"    Cataracts may develop after laser treatment, but visually significant lens opacities appear to be rare. Cataracts may be less likely to occur following photocoagulation with a diode than argon laser. In one study of 293 eyes, no visually significant cataracts occurred after diode laser treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/80\">",
"     80",
"    </a>",
"    ]. In contrast, cataracts formed in 1 to 6 percent of eyes following argon laser treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. A rare complication of laser treatment is angle-closure glaucoma seen two to five weeks after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of glaucoma in infants and children\", section on 'Retinopathy of prematurity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13520345\">",
"    <span class=\"h3\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/44/20166?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    , an antivascular endothelial growth factor (VEGF) monoclonal antibody, is another therapy for ROP. Bevacizumab is approved for the treatment of metastatic colon cancer. It has also been used off-label to treat neovascular eye conditions, including age-related macular degeneration, diabetic retinopathy, and retinopathy of prematurity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of angiogenesis inhibitors\", section on 'Anti-VEGF neutralizing antibodies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26074?source=see_link&amp;anchor=H9#H9\">",
"     \"Age-related macular degeneration: Treatment and prevention\", section on 'Bevacizumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=see_link&amp;anchor=H18#H18\">",
"     \"Prevention and treatment of diabetic retinopathy\", section on 'VEGF inhibitors for PDR'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Potential advantages of intravitreal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/44/20166?source=see_link\">",
"     bevacizumab",
"    </a>",
"    over photocoagulation for the treatment of ROP include ease of administration (typically at the bedside) and more rapid response (because it binds VEGF directly). In addition, bevacizumab may be used in infants for whom photocoagulation is not possible (eg, those with opaque cornea or lens, vitreous haziness, poor pupillary dilation) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Potential disadvantages include the possibility of long-term systemic effects including potential damage to the brain, lungs, and kidneys, and the critical timing of the injection (too early may interfere with normal vascularization; too late may lead to early retinal detachment) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/85,87-91\">",
"     85,87-91",
"    </a>",
"    ]. The minimum effective dose has not been established. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a multicenter randomized trial comparing",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/44/20166?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and conventional laser therapy in 150 infants with stage 3+ ROP in zone I or posterior zone II, bevacizumab was associated with decreased rates of recurrence and fewer structural abnormalities (eg, macular dragging, retinal detachment) at 54 weeks&rsquo; postmenstrual age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/86\">",
"     86",
"    </a>",
"    ]. These results were statistically significant for zone I eyes but not for zone II eyes. No systemic or local toxic effects were observed; however, the study was too small to adequately assess ocular and systemic safety. Recurrence occurred later among infants treated with bevacizumab than infants treated with laser therapy (mean of 16.0 versus 6.2 weeks after treatment), suggesting that infants treated with bevacizumab may require prolonged follow-up. In a single institution series of nine patients (17 eyes) with recurrence of ROP after treatment with bevacizumab, the mean time to retreatment was 14.4 weeks (range 4 to 35 weeks), and mean postmenstrual age at retreatment was 49.3 (standard deviation 9.1) weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/92\">",
"     92",
"    </a>",
"    ]. Five of 17 eyes progressed to retinal detachment (none in the group receiving laser therapy for recurrence). In addition, all four eyes that received a second injection of bevacizumab for recurrence or persistence of ROP ultimately received laser therapy. These data suggest that laser therapy may be preferred for retreatment after initial failure using bevacizumab.",
"   </p>",
"   <p>",
"    Although the multicenter trial suggests that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/44/20166?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is efficacious in the treatment of ROP prior to the onset of retinal detachment, additional trials are necessary to determine the optimal timing, dose, and duration of effect; whether bevacizumab should be used alone or in conjunction with other treatment modalities; the long-term effect of bevacizumab on visual acuity and visual fields; the duration and frequency of follow-up; and the management of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/85-87,90,93,94\">",
"     85-87,90,93,94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Retinal detachment",
"    </span>",
"    &nbsp;&mdash;&nbsp;When ROP progresses to partial or total retinal detachment (stage 4 or 5), surgical intervention is attempted to promote reattachment and preserve vision. The procedures typically used are scleral buckling or vitrectomy. In one series, these techniques resulted in light perception or better vision in 72 percent of eyes and achieved visual acuity of",
"    <span class=\"nowrap\">",
"     20/300",
"    </span>",
"    or better in 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With scleral buckling, a silicone band is placed around the eye and tightened so that the retina is reapposed to the wall of the eye, allowing reattachment to occur. Vitrectomy involves surgical removal of the vitreous, and excision of the fibrous tissue that is placing traction on the retina. The lens sometimes is sacrificed during the procedure to promote retinal reattachment. The retina then is placed against the wall of the eye and held there by injecting perfluorocarbon gas or silicone oil to replace the vitreous. Despite successful reattachment of the retina, many patients have extremely poor vision or are blind [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/62,96-99\">",
"     62,96-99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Predictors of retinal detachment after laser treatment at threshold were identified in a retrospective case series of 262 eyes in 138 infants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/100\">",
"     100",
"    </a>",
"    ]. Retinal detachment developed in 14 percent of eyes by 6 to 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/101\">",
"     101",
"    </a>",
"    ]. Retinal detachment was more frequent in eyes with vitreous hemorrhage severe enough to completely obscure visualization of the retina and clinically important vitreous organization. Vitreous organization was defined by the presence of white, fibrous-appearing opacification of the vitreous above the",
"    <span class=\"nowrap\">",
"     vascular/avascular",
"    </span>",
"    junction. It was considered clinically important when it spanned &ge;2 contiguous clock hours or was dense enough to moderately or severely reduce visualization of the retina, but also to have been unassociated with retinal detachment at the time of initial discovery. The development of retinal detachment was not associated with prolonged activity of stage 3 disease or plus disease more than 21 days after treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;After treatment, follow-up examinations are typically performed every one to two weeks for one to two months and then at less frequent intervals depending upon the clinical course. Infants who develop ROP are at increased risk for abnormalities, including myopia, astigmatism, anisometropia, and strabismus and should be followed by an ophthalmologist [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. These problems are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and management of strabismus in children\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=see_link&amp;anchor=H3#H3\">",
"     \"Refractive errors in children\", section on 'Refractive errors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions to prevent or limit the progression of retinopathy of prematurity (ROP) have been unsuccessful, although further evaluation may be needed. Because oxidant injury contributes to ROP, antioxidant therapies, such as vitamin E, D-penicillamine, and limited exposure to light, have been tested.",
"   </p>",
"   <p>",
"    In a meta-analysis of randomized trials of supplemental vitamin E, the treatment group was less likely than was the control to develop stage 3 or greater ROP (2.4 versus 5.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/105\">",
"     105",
"    </a>",
"    ]. However, vitamin E increased the rate of sepsis and necrotizing enterocolitis in one study, and the overall risk-benefit ratio is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    D-penicillamine reduced the incidence of ROP in two randomized trials evaluated in a systematic review (relative risk 0.09; 95% confidence interval (CI) 0.01-0.71) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/107\">",
"     107",
"    </a>",
"    ]. However, no intravenous preparation is available, and further studies are needed to evaluate adverse effects. In a controlled trial, reduced exposure to ambient light did not change the incidence of ROP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supplemental oxygen therapy has been tested in infants with severe ROP because retinal hypoxia contributes to neovascularization. In the STOP-ROP trial, 649 infants with prethreshold ROP were randomly assigned to maintain oxygen saturation at 96 to 99 (supplemental) or 89 to 94 (conventional) percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/32/10762/abstract/108\">",
"     108",
"    </a>",
"    ]. The rate of progression to threshold was similar in the two groups (odds ratio, 0.72; 95% CI 0.52-1.01). Further analysis suggested that the treatment may be more effective in infants without plus disease (32 versus 46 percent rate of progression). However, adverse pulmonary effects occurred more frequently in the supplemental group. Treated infants were more likely to have pneumonia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exacerbations of chronic lung disease (13.2 versus 8.5 percent) and to remain hospitalized, on oxygen, and on diuretics at 50 postmenstrual weeks.",
"   </p>",
"   <p>",
"    Based upon the available evidence, we recommend prompt detection and treatment of ROP. In addition, episodes of physiologic instability that may increase the risk of ROP should be avoided if possible. Additional preventive measures await further study. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/28/19905?source=see_link\">",
"       \"Patient information: Retinopathy of prematurity (ROP) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retinopathy of prematurity (ROP) is a developmental proliferative vascular disorder that occurs in the retina of preterm infants with incomplete retinal vascularization. It is a common cause of childhood blindness in the United States. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence and severity of ROP increase with decreasing gestational age (GA) and birth weight. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The International Classification for ROP provides a uniform approach to documenting the extent and severity of disease. It is based upon four features: zone (",
"      <a class=\"graphic graphic_figure graphicRef81495 \" href=\"UTD.htm?8/3/8254\">",
"       figure 2",
"      </a>",
"      ), stage, extent, and presence or absence of plus disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ROP typically begins about 34 weeks&rsquo; postmenstrual age (PMA), but may be seen as early as 30 to 32 weeks. It advances irregularly until 40 to 45 weeks&rsquo; PMA, but resolves spontaneously in the majority of infants. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We screen for ROP in all infants with birth weight &le;1500 g or a GA of &lt;30 weeks, as well as those with birth weight between 1500 g and 2000 g or a GA of &ge;30 weeks whose clinical course places them at increased risk for ROP. The screening evaluation consists of a comprehensive eye examination performed by an ophthalmologist with expertise in neonatal disorders. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We initiate screening examinations at four to six weeks after birth, depending upon the GA (",
"      <a class=\"graphic graphic_table graphicRef77995 \" href=\"UTD.htm?28/28/29131\">",
"       table 1",
"      </a>",
"      ). Additional examinations are performed at intervals of one to three weeks until the retinal vessels have completely grown out to the ora serrata. If ROP develops, the eyes are examined more frequently, depending upon the severity of disease and rate of progression. Screening examinations continue until ROP regresses and the vasculature matures or treatment is needed. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Evaluation schedule'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Discontinuation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment for ROP is normally indicated for infants who have progressed to high-risk prethreshold disease and all infants with threshold disease. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Indications for treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment consists of ablation of the peripheral avascular retina, usually by laser photocoagulation.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/44/20166?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      is effective in treating some forms of severe ROP, but long-term systemic and ocular outcomes are unknown. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Modalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After treatment, follow-up examinations are performed every one to two weeks for one to two months and then at less frequent intervals depending upon the clinical course. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/1\">",
"      Hittner HM, Hirsch NJ, Rudolph AJ. Assessment of gestational age by examination of the anterior vascular capsule of the lens. J Pediatr 1977; 91:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/2\">",
"      Robinson J, Fielder AR. Pupillary diameter and reaction to light in preterm neonates. Arch Dis Child 1990; 65:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/3\">",
"      Isenberg SJ, Apt L, McCarty J, et al. Development of tearing in preterm and term neonates. Arch Ophthalmol 1998; 116:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/4\">",
"      Young TL, Anthony DC, Pierce E, et al. Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. J AAPOS 1997; 1:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/5\">",
"      Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996; 114:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/6\">",
"      Stone J, Chan-Ling T, Pe'er J, et al. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996; 37:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/7\">",
"      Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995; 113:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/8\">",
"      Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995; 92:10457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/9\">",
"      Vannay A, Dunai G, B&aacute;ny&aacute;sz I, et al. Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. Pediatr Res 2005; 57:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/10\">",
"      Sood BG, Madan A, Saha S, et al. Perinatal systemic inflammatory response syndrome and retinopathy of prematurity. Pediatr Res 2010; 67:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/11\">",
"      Hellstr&ouml;m A, Carlsson B, Niklasson A, et al. IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab 2002; 87:3413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/12\">",
"      Smith LE. IGF-1 and retinopathy of prematurity in the preterm infant. Biol Neonate 2005; 88:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/13\">",
"      Mandal K, Drury JA, Clark DI. An unusual case of retinopathy of prematurity. J Perinatol 2007; 27:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/14\">",
"      Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A 2001; 98:5804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/15\">",
"      Hellstr&ouml;m A, Engstr&ouml;m E, H&aring;rd AL, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003; 112:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/16\">",
"      L&ouml;fqvist C, Andersson E, Sigurdsson J, et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol 2006; 124:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/17\">",
"      Villegas Becerril E, Fern&aacute;ndez Molina F, Gonz&aacute;lez R, Gallardo Galera JM. [Serum IGF-I levels in retinopathy of prematurity. New indications for ROP screening]. Arch Soc Esp Oftalmol 2005; 80:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/18\">",
"      P&eacute;rez-Mu&ntilde;uzuri A, Fern&aacute;ndez-Lorenzo JR, Couce-Pico ML, et al. Serum levels of IGF1 are a useful predictor of retinopathy of prematurity. Acta Paediatr 2010; 99:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/19\">",
"      Shih SC, Ju M, Liu N, Smith LE. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest 2003; 112:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/20\">",
"      Hamilton R, Bradnam MS, Dudgeon J, Mactier H. Maturation of rod function in preterm infants with and without retinopathy of prematurity. J Pediatr 2008; 153:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/21\">",
"      Good WV. Retinopathy of prematurity and the peripheral retina. J Pediatr 2008; 153:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/22\">",
"      Hussain N, Clive J, Bhandari V. Current incidence of retinopathy of prematurity, 1989-1997. Pediatrics 1999; 104:e26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/23\">",
"      Palmer EA, Flynn JT, Hardy RJ, et al. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1991; 98:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/24\">",
"      Darlow BA, Hutchinson JL, Henderson-Smart DJ, et al. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics 2005; 115:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/25\">",
"      Haines L, Fielder AR, Baker H, Wilkinson AR. UK population based study of severe retinopathy of prematurity: screening, treatment, and outcome. Arch Dis Child Fetal Neonatal Ed 2005; 90:F240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/26\">",
"      Todd DA, Wright A, Smith J, NICUS Group. Severe retinopathy of prematurity in infants &lt;30 weeks' gestation in New South Wales and the Australian Capital Territory from 1992 to 2002. Arch Dis Child Fetal Neonatal Ed 2007; 92:F251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/27\">",
"      Good WV, Hardy RJ, Dobson V, et al. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics 2005; 116:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/28\">",
"      Gilbert C, Fielder A, Gordillo L, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 2005; 115:e518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/29\">",
"      Seiberth V, Linderkamp O. Risk factors in retinopathy of prematurity. a multivariate statistical analysis. Ophthalmologica 2000; 214:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/30\">",
"      Hagadorn JI, Richardson DK, Schmid CH, Cole CH. Cumulative illness severity and progression from moderate to severe retinopathy of prematurity. J Perinatol 2007; 27:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/31\">",
"      Lad EM, Hernandez-Boussard T, Morton JM, Moshfeghi DM. Incidence of retinopathy of prematurity in the United States: 1997 through 2005. Am J Ophthalmol 2009; 148:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/32\">",
"      Chavez-Valdez R, McGowan J, Cannon E, Lehmann CU. Contribution of early glycemic status in the development of severe retinopathy of prematurity in a cohort of ELBW infants. J Perinatol 2011; 31:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/33\">",
"      Kaempf JW, Kaempf AJ, Wu Y, et al. Hyperglycemia, insulin and slower growth velocity may increase the risk of retinopathy of prematurity. J Perinatol 2011; 31:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/34\">",
"      Bharwani SK, Dhanireddy R. Systemic fungal infection is associated with the development of retinopathy of prematurity in very low birth weight infants: a meta-review. J Perinatol 2008; 28:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/35\">",
"      Hellstr&ouml;m A, H&aring;rd AL, Engstr&ouml;m E, et al. Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics 2009; 123:e638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/36\">",
"      L&ouml;fqvist C, Hansen-Pupp I, Andersson E, et al. Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I. Arch Ophthalmol 2009; 127:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/37\">",
"      PATZ A, HOECK LE, DE LA CRUZ E. Studies on the effect of high oxygen administration in retrolental fibroplasia. I. Nursery observations. Am J Ophthalmol 1952; 35:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/38\">",
"      Flynn JT, Bancalari E, Snyder ES, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 1992; 326:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/39\">",
"      SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Finer NN, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 2010; 362:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/40\">",
"      Noyola DE, Bohra L, Paysse EA, et al. Association of candidemia and retinopathy of prematurity in very low birthweight infants. Ophthalmology 2002; 109:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/41\">",
"      An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity. Arch Ophthalmol 1984; 102:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/42\">",
"      International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005; 123:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/43\">",
"      Katz X, Kychenthal A, Dorta P. Zone I retinopathy of prematurity. J AAPOS 2000; 4:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/44\">",
"      Wallace DK, Kylstra JA, Chesnutt DA. Prognostic significance of vascular dilation and tortuosity insufficient for plus disease in retinopathy of prematurity. J AAPOS 2000; 4:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/45\">",
"      Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group. The Early Treatment for Retinopathy Of Prematurity Study: structural findings at age 2 years. Br J Ophthalmol 2006; 90:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/46\">",
"      Repka MX, Palmer EA, Tung B. Involution of retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 2000; 118:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/47\">",
"      Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: natural history ROP: ocular outcome at 5(1/2) years in premature infants with birth weights less than 1251 g. Arch Ophthalmol 2002; 120:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/48\">",
"      Fierson WM, American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, et al. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2013; 131:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/49\">",
"      Clarke WN, Hodges E, Noel LP, et al. The oculocardiac reflex during ophthalmoscopy in premature infants. Am J Ophthalmol 1985; 99:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/50\">",
"      Lee SK, Normand C, McMillan D, et al. Evidence for changing guidelines for routine screening for retinopathy of prematurity. Arch Pediatr Adolesc Med 2001; 155:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/51\">",
"      . Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003; 121:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/52\">",
"      Wu C, Vanderveen DK, Hellstr&ouml;m A, et al. Longitudinal postnatal weight measurements for the prediction of retinopathy of prematurity. Arch Ophthalmol 2010; 128:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/53\">",
"      Binenbaum G, Ying GS, Quinn GE, et al. A clinical prediction model to stratify retinopathy of prematurity risk using postnatal weight gain. Pediatrics 2011; 127:e607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/54\">",
"      Wu C, L&ouml;fqvist C, Smith LE, et al. Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity. Arch Ophthalmol 2012; 130:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/55\">",
"      Binenbaum G, Ying GS, Quinn GE, et al. The CHOP Postnatal Weight Gain, Birth Weight, and Gestational Age Retinopathy of Prematurity Risk Model. Arch Ophthalmol 2012; 130:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/56\">",
"      Zepeda-Romero LC, H&aring;rd AL, Gomez-Ruiz LM, et al. Prediction of retinopathy of prematurity using the screening algorithm WINROP in a Mexican population of preterm infants. Arch Ophthalmol 2012; 130:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/57\">",
"      Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1990; 108:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/58\">",
"      Reynolds JD, Hardy RJ, Kennedy KA, et al. Lack of efficacy of light reduction in preventing retinopathy of prematurity. Light Reduction in Retinopathy of Prematurity (LIGHT-ROP) Cooperative Group. N Engl J Med 1998; 338:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/59\">",
"      Reynolds JD, Dobson V, Quinn GE, et al. Evidence-based screening criteria for retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHT-ROP studies. Arch Ophthalmol 2002; 120:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/60\">",
"      Christiansen SP, Dobson V, Quinn GE, et al. Progression of type 2 to type 1 retinopathy of prematurity in the Early Treatment for Retinopathy of Prematurity Study. Arch Ophthalmol 2010; 128:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/61\">",
"      Aprahamian AD, Coats DK, Paysse EA, Brady-Mccreery K. Compliance with outpatient follow-up recommendations for infants at risk for retinopathy of prematurity. J AAPOS 2000; 4:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/62\">",
"      Moshfeghi AA, Banach MJ, Salam GA, Ferrone PJ. Lens-sparing vitrectomy for progressive tractional retinal detachments associated with stage 4A retinopathy of prematurity. Arch Ophthalmol 2004; 122:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/63\">",
"      Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome--structure and function. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1990; 108:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/64\">",
"      Palmer EA, Hardy RJ, Dobson V, et al. 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 2005; 123:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/65\">",
"      Hardy RJ, Palmer EA, Dobson V, et al. Risk analysis of prethreshold retinopathy of prematurity. Arch Ophthalmol 2003; 121:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/66\">",
"      Quinn GE, Dobson V, Hardy RJ, et al. Visual field extent at 6 years of age in children who had high-risk prethreshold retinopathy of prematurity. Arch Ophthalmol 2011; 129:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/67\">",
"      Early Treatment for Retinopathy of Prematurity Cooperative Group, Good WV, Hardy RJ, et al. Final visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol 2010; 128:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/68\">",
"      Early Treatment for Retinopathy of Prematurity Cooperative Group, Dobson V, Quinn GE, et al. Grating visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol 2011; 129:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/69\">",
"      Schaffer DB, Palmer EA, Plotsky DF, et al. Prognostic factors in the natural course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1993; 100:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/70\">",
"      Andersen CC, Phelps DL. Peripheral retinal ablation for threshold retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev 2000; :CD001693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/71\">",
"      Simpson JL, Melia M, Yang MB, et al. Current role of cryotherapy in retinopathy of prematurity: a report by the American Academy of Ophthalmology. Ophthalmology 2012; 119:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/72\">",
"      Paysse EA, Lindsey JL, Coats DK, et al. Therapeutic outcomes of cryotherapy versus transpupillary diode laser photocoagulation for threshold retinopathy of prematurity. J AAPOS 1999; 3:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/73\">",
"      White JE, Repka MX. Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: 3-year outcome. J Pediatr Ophthalmol Strabismus 1997; 34:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/74\">",
"      McGregor ML, Wherley AJ, Fellows RR, et al. A comparison of cryotherapy versus diode laser retinopexy in 100 consecutive infants treated for threshold retinopathy of prematurity. J AAPOS 1998; 2:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/75\">",
"      McNamara JA, Tasman W, Vander JF, Brown GC. Diode laser photocoagulation for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1992; 110:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/76\">",
"      McNamara JA, Tasman W, Brown GC, Federman JL. Laser photocoagulation for stage 3+ retinopathy of prematurity. Ophthalmology 1991; 98:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/77\">",
"      Laser therapy for retinopathy of prematurity. Laser ROP Study Group. Arch Ophthalmol 1994; 112:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/78\">",
"      Ng EY, Connolly BP, McNamara JA, et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology 2002; 109:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/79\">",
"      Connolly BP, Ng EY, McNamara JA, et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome. Ophthalmology 2002; 109:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/80\">",
"      Paysse EA, Miller A, Brady McCreery KM, Coats DK. Acquired cataracts after diode laser photocoagulation for threshold retinopathy of prematurity. Ophthalmology 2002; 109:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/81\">",
"      O'Neil JW, Hutchinson AK, Saunders RA, Wilson ME. Acquired cataracts after argon laser photocoagulation for retinopathy of prematurity. J AAPOS 1998; 2:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/82\">",
"      Christiansen SP, Bradford JD. Cataract in infants treated with argon laser photocoagulation for threshold retinopathy of prematurity. Am J Ophthalmol 1995; 119:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/83\">",
"      Trigler L, Weaver RG Jr, O'Neil JW, et al. Case series of angle-closure glaucoma after laser treatment for retinopathy of prematurity. J AAPOS 2005; 9:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/84\">",
"      Law JC, Recchia FM, Morrison DG, et al. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS 2010; 14:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/85\">",
"      Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol 2009; 148:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/86\">",
"      Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/87\">",
"      Reynolds JD. Bevacizumab for retinopathy of prematurity. N Engl J Med 2011; 364:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/88\">",
"      Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008; 246:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/89\">",
"      Zepeda-Romero LC, Liera-Garcia JA, Guti&eacute;rrez-Padilla JA, et al. Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity. Eye (Lond) 2010; 24:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/90\">",
"      Moshfeghi DM, Berrocal AM. Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology 2011; 118:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/91\">",
"      H&aring;rd AL, Hellstr&ouml;m A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review. Acta Paediatr 2011; 100:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/92\">",
"      Hu J, Blair MP, Shapiro MJ, et al. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 2012; 130:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/93\">",
"      Sapieha P, Joyal JS, Rivera JC, et al. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest 2010; 120:3022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/94\">",
"      Darlow BA, Ells AL, Gilbert CE, et al. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed 2013; 98:F170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/95\">",
"      Trese MT, Droste PJ. Long-term postoperative results of a consecutive series of stages 4 and 5 retinopathy of prematurity. Ophthalmology 1998; 105:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/96\">",
"      Hubbard GB 3rd, Cherwick DH, Burian G. Lens-sparing vitrectomy for stage 4 retinopathy of prematurity. Ophthalmology 2004; 111:2274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/97\">",
"      Lakhanpal RR, Sun RL, Albini TA, Holz ER. Anatomic success rate after 3-port lens-sparing vitrectomy in stage 4A or 4B retinopathy of prematurity. Ophthalmology 2005; 112:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/98\">",
"      Prenner JL, Capone A Jr, Trese MT. Visual outcomes after lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Ophthalmology 2004; 111:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/99\">",
"      Repka MX, Tung B, Good WV, et al. Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP). Arch Ophthalmol 2006; 124:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/100\">",
"      Coats DK, Miller AM, Hussein MA, et al. Involution of retinopathy of prematurity after laser treatment: factors associated with development of retinal detachment. Am J Ophthalmol 2005; 140:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/101\">",
"      Coats DK, Miller AM, Brady McCreery KM, et al. Involution of threshold retinopathy of prematurity after diode laser photocoagulation. Ophthalmology 2004; 111:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/102\">",
"      Laws D, Shaw DE, Robinson J, et al. Retinopathy of prematurity: a prospective study. Review at six months. Eye (Lond) 1992; 6 ( Pt 5):477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/103\">",
"      Quinn GE, Dobson V, Davitt BV, et al. Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology 2008; 115:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/104\">",
"      Davitt BV, Dobson V, Quinn GE, et al. Astigmatism in the Early Treatment for Retinopathy Of Prematurity Study: findings to 3 years of age. Ophthalmology 2009; 116:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/105\">",
"      Raju TN, Langenberg P, Bhutani V, Quinn GE. Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. J Pediatr 1997; 131:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/106\">",
"      Johnson L, Bowen FW Jr, Abbasi S, et al. Relationship of prolonged pharmacologic serum levels of vitamin E to incidence of sepsis and necrotizing enterocolitis in infants with birth weight 1,500 grams or less. Pediatrics 1985; 75:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/107\">",
"      Phelps DL, Lakatos L, Watts JL. D-Penicillamine for preventing retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev 2001; :CD001073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/32/10762/abstract/108\">",
"      Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 2000; 105:295.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6263 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-190.92.87.104-ACD0464BDC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10762=[""].join("\n");
var outline_f10_32_10762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OCULAR CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Normal vascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vascularization in ROP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Photoreceptor development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Zone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Stage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Extent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Plus disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Threshold ROP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prethreshold ROP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Screening criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Evaluation schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Discontinuation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Modalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Cryotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Photocoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13520345\">",
"      - Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6263\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6263|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/27/19903\" title=\"figure 1\">",
"      Retinal vascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/3/8254\" title=\"figure 2\">",
"      International classification of ROP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/31/11762\" title=\"figure 3\">",
"      Stage 4 ROP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6263|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/62/44015\" title=\"picture 1\">",
"      Stage 1 ROP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/27/6590\" title=\"picture 2\">",
"      Stage II ROP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/6/16495\" title=\"picture 3\">",
"      Stage 3 ROP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/43/14000\" title=\"picture 4\">",
"      Stage 5 ROP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/32/6671\" title=\"picture 5\">",
"      ROP Plus disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6263|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/28/29131\" title=\"table 1\">",
"      Timing first exam for ROP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26074?source=related_link\">",
"      Age-related macular degeneration: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=related_link\">",
"      Anemia of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=related_link\">",
"      Overview of amblyopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=related_link\">",
"      Overview of glaucoma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=related_link\">",
"      Oxygen monitoring and therapy in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/28/19905?source=related_link\">",
"      Patient information: Retinopathy of prematurity (ROP) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=related_link\">",
"      Refractive errors in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_32_10763="NCI CTCAE grading scale for fatigue v4";
var content_f10_32_10763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    NCI Common Terminology Criteria for Adverse Events (CTCAE) grading scale for fatigue",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Fatigue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Fatigue relieved by rest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Fatigue not relieved by rest; limiting instrumental ADL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        Fatigue not relieved by rest; limiting self-care ADL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADL: activities of daily living; NCI: National Cancer Institute.",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Common Terminology Criteria for Adverse Events, version 4.0, June 2010, National Institutes of Health, National Cancer Institute, file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10763=[""].join("\n");
var outline_f10_32_10763=null;
var title_f10_32_10764="Sigmoid and transverse loops";
var content_f10_32_10764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency and types of loops observed during intubation utilizing magnetic imaging",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Loop",
"      </td>",
"      <td class=\"subtitle1\">",
"       Total (n=100)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Males (n=48)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Females (n=52)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       9",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"       Sigmoid loops",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N-sigmoid spiral",
"      </td>",
"      <td class=\"sublist_other\">",
"       79",
"      </td>",
"      <td class=\"sublist_other\">",
"       38",
"      </td>",
"      <td class=\"sublist_other\">",
"       41",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Alpha",
"      </td>",
"      <td class=\"sublist_other\">",
"       12",
"      </td>",
"      <td class=\"sublist_other\">",
"       5",
"      </td>",
"      <td class=\"sublist_other\">",
"       7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Reverse alpha",
"      </td>",
"      <td class=\"sublist_other\">",
"       11",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"      <td class=\"sublist_other\">",
"       9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Reverse sigmoid spiral",
"      </td>",
"      <td class=\"sublist_other\">",
"       1",
"      </td>",
"      <td class=\"sublist_other\">",
"       0",
"      </td>",
"      <td class=\"sublist_other\">",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"       Transverse loops",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Deep transverse",
"      </td>",
"      <td class=\"sublist_other\">",
"       34",
"      </td>",
"      <td class=\"sublist_other\">",
"       15",
"      </td>",
"      <td class=\"sublist_other\">",
"       19",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Reverse splenic",
"      </td>",
"      <td class=\"sublist_other\">",
"       3",
"      </td>",
"      <td class=\"sublist_other\">",
"       1",
"      </td>",
"      <td class=\"sublist_other\">",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Gamma",
"      </td>",
"      <td class=\"sublist_other\">",
"       1",
"      </td>",
"      <td class=\"sublist_other\">",
"       0",
"      </td>",
"      <td class=\"sublist_other\">",
"       1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10764=[""].join("\n");
var outline_f10_32_10764=null;
var title_f10_32_10765="Genetic mimics of vascular or prenatal insults";
var content_f10_32_10765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetic conditions associated with microcephaly and neuroradiologic abnormalities mimicking vascular damage or prenatal infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Genetic condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Phenocopy*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Selected reference(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aicardi-Goutier&egrave;s syndrome (also known as pseudo-TORCH and allelic with Cree encephalitis (at least 5 genes, common))",
"       </td>",
"       <td>",
"        Congenital infection with thrombocytopenia, increased production of alpha-interferon, ulcerative skin lesions",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudo-TORCH syndrome type b",
"       </td>",
"       <td>",
"        Distinct pattern of band-like intracranial calcification, simplified gyration and polymicrogyria; severe postnatal microcephaly, seizures, developmental arrest",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulphite oxidase deficiency",
"       </td>",
"       <td>",
"        Neonatal encephalopathy; neuroradiology and pathology can mimic perinatal asphyxia",
"       </td>",
"       <td>",
"        3, 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitochondrial/respiratory chain abnormality",
"       </td>",
"       <td>",
"        Disrupted brain development with congenital infection-like calcifications, and a complex neuronal migration disorder",
"       </td>",
"       <td>",
"        5, 6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PEHO-like syndrome",
"       </td>",
"       <td>",
"        Encephalopathy with hypoxic ischemic changes on MRI",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fetal brain disruption sequence",
"       </td>",
"       <td>",
"        Traumatic brain destruction",
"       </td>",
"       <td>",
"        8, 9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystic leukoencephalopathy",
"       </td>",
"       <td>",
"        Congenital CMV clinically and neuroradiologically",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilateral porencephaly; cerebellar or vermis hypoplasia or aplasia; congenital heart defect",
"       </td>",
"       <td>",
"        Bilateral porencephaly (\"basket brain\") may resemble middle cerebral artery infarct",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Phenocopy: a nongenetic condition with an appearance that is similar to that caused by a specific genotype.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Stephenson, JB. Aicardi-Goutier&egrave;s syndrome (AGS). Eur J Paediatr Neurol 2008; 12:355.",
"       </li>",
"       <li>",
"        Briggs, TA, Wolf, NI, D'Arrigo, S, et al. Band-like intracranial calcification with simplified gyration and polymicrogyria: a distinct \"pseudo-TORCH\" phenotype. Am J Med Genet A 2008; 146A:3173.",
"       </li>",
"       <li>",
"        Hobson, EE, Thomas, S, Crofton, PM, et al. Isolated sulphite oxidase deficiency mimics the features of hypoxic ischaemic encephalopathy. Eur J Pediatr 2005; 164:655.",
"       </li>",
"       <li>",
"        Hoffmann, C, Ben-Zeev, B, Anikster, Y, et al. Magnetic resonance imaging and magnetic resonance spectroscopy in isolated sulfite oxidase deficiency. J Child Neurol 2007; 22:1214.",
"       </li>",
"       <li>",
"        van Straaten, HL, van Tintelen, JP, Trijbels, JM, et al. Neonatal lactic acidosis, complex I/IV deficiency, and fetal cerebral disruption. Neuropediatrics 2005; 36:193.",
"       </li>",
"       <li>",
"        Samson, JF, Barth, PG, de Vries, JI, et al. Familial mitochondrial encephalopathy with fetal ultrasonographic ventriculomegaly and intracerebral calcifications. Eur J Pediatr 1994; 153:510.",
"       </li>",
"       <li>",
"        Longman, C, Tolmie, J, McWilliam, R, MacLennan, A. Cranial magnetic resonance imaging mistakenly suggests prenatal ischaemia in PEHO-like syndrome. Clin Dysmorphol 2003; 12:133.",
"       </li>",
"       <li>",
"        Schram, A, Kroes, HY, Sollie, K, et al. Hereditary fetal brain degeneration resembling fetal brain disruption sequence in two sibships. Am J Med Genet A 2004; 127A:172.",
"       </li>",
"       <li>",
"        Behunova, J, Zavadilikova, E, Bozoglu, TM, et al. Familial microhydranencephaly, a family that does not map to 16p13.13-p12.2:: relationship with hereditary fetal brain degeneration and fetal brain disruption sequence. Clin Dysmorphol 2010; 19:107.",
"       </li>",
"       <li>",
"        Henneke, M, Diekmann, S, Ohlenbusch, A, et al. RNASET2-deficient cystic leukoencephalopathy resembles congenital cytomegalovirus brain infection. Nat Genet 2009; 41:773.",
"       </li>",
"       <li>",
"        Bonnemann, CG, Meinecke, P. Bilateral porencephaly, cerebellar hypoplasia, and internal malformations: two siblings representing a probably new autosomal recessive entity. Am J Med Genet 1996; 63:428.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10765=[""].join("\n");
var outline_f10_32_10765=null;
var title_f10_32_10766="View through a rigid bronchoscope - mouth to epiglottis";
var content_f10_32_10766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/71905/rgdintbi_conv.mp4?title=View+through+a+rigid+bronchoscope+-+mouth+to+epiglottis\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rigid broncoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Video shows the view through a rigid bronchoscope as it is passed from the mouth to the epiglottis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henri G Colt, MD and Praveen Mathur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10766=[""].join("\n");
var outline_f10_32_10766=null;
var title_f10_32_10767="Normal wrist radiograph";
var content_f10_32_10767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal wrist radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anterior-posterior view of the wrist is normal. The width of the articular cartilage is 2 mm and is identical to the width of the intercarpal joints.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_32_10767=[""].join("\n");
var outline_f10_32_10767=null;
